

7. Literatur

Abbas A, Gorelik G, Carbini LA, Scicli AG. (1997). Angiotensin-(1-7) induces bradykinin-mediated hypotensive responses in anesthetized rats. *Hypertension*. **30**(2Pt 1): 217-221.

AbdAlla S, Lothar H, Abdel-tawad AM, Quitterer U. (2001a). The angiotensin II AT2 is an AT1 receptor antagonist. *J. Bio.l Chem.* **276**(43): 39721-39726.

AbdAlla S, Lothar H, el Massiery A, Quitterer U. (2001b). Increased AT(1) receptor heterodimers in preeclampsia mediate enhanced angiotensin II responsiveness. *Nat. Med.* **7**(9): 1003-1009.

AbdAlla S, Lothar H, Quitterer U. (2000). AT1-receptor heterodimers show enhanced G-protein activation and altered receptor sequestration. *Nature*. **7**;407(6800): 94-98.

Alfie ME, Sigmon DH, Pomposiello SI, Carretero OA. (1997). Effect of high salt intake in mutant mice lacking bradykinin-B2 receptors. *Hypertension*. **29**(1 Pt 2): 483-487.

Alfie ME, Yang XP, Hess F, Carretero OA. (1996). Salt-sensitive hypertension in bradykinin B2 receptor knockout mice. *Biochem. Biophys. Res. Commun.* **224**(3): 625-630.

Allard MF, Emanuel PG, Russell JA, Bishop SP, Digerness SB, Anderson PG. (1994). Preischemic glycogen reduction or glycolytic inhibition improves postischemic recovery of hypertrophied rat hearts. *Am. J. Physiol.* **267**(1 Pt 2): H66-74.

Allen LF, Lefkowitz RJ, Caron MG, Cotecchia S. (1999). G-protein-coupled receptor genes as protooncogenes: constitutively activating mutation of the alpha 1B-adrenergic receptor enhances mitogenesis and tumorigenicity. *Proc. Natl. Acad. Sci. U S A.* **88**(24): 11354-11358.

Allogho SN, Gobeil F, Pheng HL, Nguyen-Le XK, Neugebauer W, Regoli D. (1995). Kinin B1 and B2 receptors in the mouse. *Can. J. Physiol. Pharmacol.* **73**(12): 1759-1764.

Angers M, Drouin R, Bachvarova M, Paradis I, Bissel B, Hiromura M, Usheva A, Bachvarov DR. (2005). *In vivo* DNase I-mediated footprinting analysis along the human bradykinin B1 receptor (BDKRB1) gene promoter: evidence for cell-specific regulation. *Biochem. J.* **389**(Pt 1): 37-46.

Angers M, Drouin R, Bachvarova M, Paradis I, Marceau F, Bachvarov DR. (2000). *In vivo* protein-DNA interactions at the kinin B(1) receptor gene promoter: no modification on interleukin-1 beta or lipopolysaccharide induction. *J. Cell. Biochem.* **78**(2): 278-296.

Appleton I, Tomlinson A, Chander CL, Willoughby DA. (1992). Effect of endothelin-1 on croton oil-induced granulation tissue in the rat. A pharmacologic and immunohistochemical study. *Lab. Invest.* **67**(6): 703-710.

Arai N, Mitomi H, Ohtani Y, Igarashi M, Kakita A, Okayasu I. (1999). Enhanced epithelial cell turnover associated with p53 accumulation and high p21WAF1/CIP1 expression in ulcerative colitis. *Mod. Pathol.* **12**(6): 604-611.

Arison RN, Feudale EL. (1967). Induction of renal tumour by streptozotocin in rats. *Nature.* **214**(94): 1254-1255.

Austin CE, Faussner A, Robinson HE, Chakravarty S, Kyle DJ, Bathon JM, Proud D. (1997). Stable expression of the human kinin B1 receptor in Chinese hamster ovary cells. Characterization of ligand binding and effector pathways. *J. Biol. Chem.* **272**(17): 11420-11425.

Bachvarov DR, Landry M, Houle S, Pare P, Marceau F. (1998). Altered frequency of a promoter polymorphic allele of the kinin B1 receptor gene in inflammatory bowel disease. *Gastroenterology.* **115**(5): 1045-1048.

Bachvarov DR, Landry M, Pelletier I, Chevrette M, Betard C, Houde I, Bergeron J, Lebel M, Marceau F. (1998) Characterization of two polymorphic sites in the human kinin B1 receptor gene: altered frequency of an allele in patients with a history of end-stage renal failure. *J. Am. Soc. Nephrol.* **9**(4): 598-604.

Bachvarov DR, Hess JF, Menke JG, Larrivee JF, Marceau F. (1996). Structure and genomic organization of the human B1 receptor gene for kinins (BDKRB1). *Genomics.* **33**(3): 374-381.

Bachvarov DR, Saint-Jacques E, Larrivee JF, Levesque L, Rioux F, Drapeau G, Marceau F. (1995). Cloning and pharmacological characterization of the rabbit bradykinin B2 receptor. *J. Pharmacol. Exp. Ther.* **275**(3): 1623-1630.

Bader M, Ganten D. (2000). Regulation of renin: new evidence from cultured cells and genetically modified mice. *J. Mol. Med.* **78**(3): 130-139.

Bajic VB, Seah SH. (2003). Dragon gene start finder: an advanced system for finding approximate locations of the start of gene transcriptional units. *Genome. Res.* **13**(8): 1923-1929.

Baker KM, Chernin MI, Wixson SK, Aceto JF. (1990). Renin-angiotensin system involvement in pressure-overload cardiac hypertrophy in rats. *Am. J. Physiol.* **259**(2 Pt 2): H324-332.

Balligand JL, Ungureanu D, Kelly RA, Kobzik L, Pimental D, Michel T, Smith TW. (1993). Abnormal contractile function due to induction of nitric oxide synthesis in rat cardiac myocytes follows exposure to activated macrophage-conditioned medium. *J. Clin. Invest.* **91**(5): 2314-2319.

- Banes AK, Shaw S, Jenkins J, Redd H, Amiri F, Pollock DM, Marrero MB. (2004)** Angiotensin II blockade prevents hyperglycemia-induced activation of JAK and STAT proteins in diabetic rat kidney glomeruli. *Am. J. Physiol. Renal. Physiol.* **286**(4): F653-659.
- Bao G, Gohlke P, Qadri F, Unger T. (1992).** Chronic kinin receptor blockade attenuates the antihypertensive effect of ramipril. *Hypertension.* **20**(1): 74-79.
- Bao G, Gohlke P, Unger T. (1992).** Role of bradykinin in chronic antihypertensive actions of ramipril in different hypertension models. *J. Cardiovasc. Pharmacol.* **20**(s9): S96-99.
- Baptista HA, Avellar MCW, Araujo RC, Pesquero JL, Paiva ACM, Schanstra JP, Bascands JL, Esteve JP, Bader M, Pesquero JB. (2001).** Mechanisms in the transcriptional regulation of rat bradykinin B2 receptor gene expression: cis and trans activating factors. Unpublished *NCBI Acc*: AF374005.
- Barber MN, Sampey DB, Widdop RE. (1999).** AT(2) receptor stimulation enhances antihypertensive effect of AT(1) receptor antagonist in hypertensive rats. *Hypertension.* **34**(5): 1112-1116.
- Barbul A. (1996).** Immune aspects of wound repair. *Clin. Plast. Surg.* **17**(3): 433-442.
- Bascands JL, Pecher C, Rouaud S, Emond C, Tack JL, Bastie MJ, Burch R, Regoli D, Girolami JP. (1993).** Evidence for existence of two distinct bradykinin receptors on rat mesangial cells. *Am. J. Physiol.* **264**(3 Pt 2): F548-556.
- Bastian S, Loillier B, Paquet JL, Pruneau D. (1997).** Stable expression of human kinin B1 receptor in 293 cells: pharmacological and functional characterization. *Br. J. Pharmacol.* **122**(2): 393-399.
- Baumgarten CR, Linz W, Kunkel G, Schölkens BA, Wiemer G. (1993).** Ramiprilat increases bradykinin outflow from isolated hearts of rat. *Br. J. Pharmacol.* **108**(2): 293-295.
- Baumgarten G, Knüfermann P, Kalra D, Gao F, Taffet GE, Michael L, Blackshear PJ, Carballo E, Sivasubramanian N, Mann DL. (2002).** Load-dependent and -independent regulation of proinflammatory cytokine and cytokine receptor gene expression in the adult mammalian heart. *Circulation.* **105**(18): 2192-2197.
- Benter IF, Diz DI, Ferrario CM. (1995).** Pressor and reflex sensitivity is altered in spontaneously hypertensive rats treated with angiotensin-(1-7). *Hypertension.* **26**(6 Pt 2): 1138-1144.
- Benzing T, Fleming I, Blaukat A, Müller-Esterl W, Busse R. (1999).** Angiotensin-converting enzyme inhibitor ramiprilat interferes with the sequestration of the B2 kinin receptor within the plasma membrane of native endothelial cells. *Circulation.* **99**(15): 2034-2040.

- Bernstein KE. (2002).** Two ACEs and a heart. *Nature*. **417**(6891): 799-802.
- Berridge MJ. (1993).** Inositol triphosphate and calcium signalling. *Nature*. **361**: 315-325.
- Berthiaume N, Hess F, Chen A, Regoli D, D'Orleans-Juste P. (1997).** Pharmacology of kinins in the arterial and venous mesenteric bed of normal and B2 knockout transgenic mice. *Eur. J. Pharmacol.* **333**(1): 55-61.
- Bhoola KD, Figueroa CD, Worthy K. (1992).** Bioregulation of kinins: kallikreins, kininogens and kininases. *Pharmacol. Rev.* **44**(1): 1-80.
- Blaukat A, Alla SA, Lohse MJ, Müller-Esterl W. (1996).** Ligand-induced phosphorylation/dephosphorylation of the endogenous bradykinin B2 receptor from human fibroblasts. *J. Biol. Chem.* **271**(50): 32366-32374.
- Blaukat A, Pizard A, Breit A, Wernstedt C, Alhenc-Gelas F, Müller-Esterl W, Dikic I. (2001).** Determination of bradykinin B2 receptor *in vivo* phosphorylation sites and their role in receptor function. *J. Biol. Chem.* **276**(44): 40431-40440.
- Blum A. (1996).** Interleukin-1 in acute myocardial infarction. *Lancet*. **347**(8993): 56.
- Blum A, Miller H. (2001).** Pathophysiological role of cytokines in congestive heart failure. *Annu. Rev. Med.* **52**: 15-27.
- Blum A, Sclarovsky S, Rehavia E, Shohat B. (1994).** Levels of T-lymphocyte subpopulations, interleukin-1 beta, and soluble interleukin-2 receptor in acute myocardial infarction. *Am. Heart J.* **127**(5): 1226-1230.
- Border WA, Noble N. (2001).** Maximizing hemodynamic-independent effects of angiotensin II antagonists in fibrotic diseases. *Semin Nephrol.* **21**(6): 563-572.
- Borkowski JA, Ransom RW, Seabrook GR, Trumbauer M, Chen H, Hill RG, Strader CD, Hess JF. (1995).** Targeted disruption of a B2 bradykinin receptor gene in mice eliminates bradykinin action in smooth muscle and neurons. *J. Biol. Chem.* **270**(23): 13706-13710.
- Bouchard JF, Chouinard J, Lamontagne D. (1998).** Role of B1 receptors in the endothelial protective effect of ischaemic preconditioning. *Arch. Mal. Coeur. Vaiss.* **91**(8): 941-945.
- Boulanger CM, Caputo L, Levy BI. (1995).** Endothelial AT1-mediated release of nitric oxide decreases angiotensin II contractions in rat carotid artery. *Hypertension.* **26**(5): 752-757.
- Bouvier M. (2001).** Oligomerization of G-protein-coupled transmitter receptors. *Nat. Rev. Neurosc.* **2**(4): 274-286.

Brands MW, Fitzgerald SM. (2002). Blood pressure control early in diabetes: a balance between angiotensin II and nitric oxide. *Clin. Exp. Pharmacol. Physiol.* **29**(1-2): 127-131.

Braun A, Kammerer S, Böhme E, Müller B, Roscher AA. (1995). Identification of polymorphic sites of the human bradykinin B2 receptor gene. *Biochem. Biophys. Res. Commun.* **211**(1): 234-240.

Braunwald E. (1997). Shattuck lecture--cardiovascular medicine at the turn of the millennium: triumphs, concerns, and opportunities. *N. Engl. J. Med.* **337**(19): 1360-1369.

Braunwald E, Zipes DP, Libby P. (2001). „Heart Disease“. A textbook of cardiovascular medicine (6th edition). *W. B. Saunders Publishing Company.*

Britos J, Nolly H. (1981). Kinin-forming enzyme of rat cardiac tissue. Subcellular distribution and biochemical properties. *Hypertension.* **3**(6 Pt 2): II-42-45.

Brosnihan KB, Li P, Ferrario CM. (1996). Angiotensin-(1-7) dilates canine coronary arteries through kinins and nitric oxide. *Hypertension.* **27**(3 Pt 2): 523-528.

Brown HB, Waugh NR, Jennings PE. (1992). Microangiopathy as a prognostic indicator in diabetic patients suffering from acute myocardial infarction. *Scott. Med. J.* **37**(2): 44-46.

Brull D, Dhamrait S, Myerson S, Erdmann J, Woods D, World M, Pennell D, Humphries S, Regitz-Zagrosek V, Montgomery H. (2001). Bradykinin B2BKR receptor polymorphism and left-ventricular growth response. *Lancet.* **358**(9288): 1155-1156.

Burch RM, Connor JR, Axelrod J. (1988). Interleukin 1 amplifies receptor-mediated activation of phospholipase A2 in 3T3 fibroblasts. *Proc. Natl. Acad. Sci. U S A.* **85**(17): 6306-6309.

Campagnole-Santos MJ, Heringer SB, Batista EN, Khosla MC, Santos RA. (1992). Differential baroreceptor reflex modulation by centrally infused angiotensin peptides. *Am. J. Physiol.* **263**(1 Pt 2): R89-94.

Campbell DJ. (2001). The kallikrein-kinin system in humans. *Clin. Exp. Pharmacol. Physiol.* **28**(12): 1060-1065.

Campbell DJ. (2003). The renin-angiotensin and the kallikrein-kinin systems. *Int. J. Biochem. Cell. Biol.* **35**(6): 784-791.

Campbell DJ, Kelly DJ, Wilkinson-Berka JL, Cooper ME, Skinner SL. (1999). Increased bradykinin and "normal" angiotensin peptide levels in diabetic Sprague-Dawley and transgenic (mRen-2)²⁷ rats. *Kidney Int.* **56**(1): 211-221.

Campbell DJ, Kladis A, Duncan AM. (1993). Bradykinin peptides in kidney, blood, and other tissues of the rat. *Hypertension*. **21**(2): 155-165.

Candido R, Srivastava P, Cooper ME, Burrell LM. (2003). Diabetes mellitus: a cardiovascular disease. *Curr. Opin. Investig. Drugs*. **4**(9): 1088-1094.

Carbini LA, Scicli AG, Carretero OA. (1993). The molecular biology of the kallikrein-kinin system: III. The human kallikrein gene family and kallikrein substrate. *J. Hypertens*. **11**(9): 893-898.

Carretero OA, Carbini LA, Scicli AG. (1993). The molecular biology of the kallikrein-kinin system: I. General description, nomenclature and the mouse gene family. *J. Hypertens*. **11**(7): 693-697.

Cayla C, Merino VF, Cabrini DA, Silva JA Jr, Pesquero JB, Bader M. (2002). Structure of the mammalian kinin receptor gene locus. *Int. Immunopharmacol*. **2**(13-14): 1721-1727.

Celentano A, Mancini FP, Crivaro M, Palmieri V, Ferrara LA, De Stefano V, Di Minno G, de Simone G. (1999). Cardiovascular risk factors, angiotensin-converting enzyme gene I/D polymorphism, and left ventricular mass in systemic hypertension. *Am. J. Cardiol*. **83**(8): 1196-1200.

Cervenka L, Maly J, Karasova L, Simova M, Vitko S, Hellerova S, Heller J, El-Dahr SS. (2001). Angiotensin II-induced hypertension in bradykinin B2 receptor knockout mice. *Hypertension*. **37**(3): 967-973.

Cesari M, Rossi GP, Pessina AC. (2002). Biological properties of the angiotensin peptides other than angiotensin II: implications for hypertension and cardiovascular diseases. *J. Hypertens*. **20**(5): 793-799.

Chahine R, Adam A, Yamaguchi N, Gaspo R, Regoli D, Nadeau R. (1993). Protective effects of bradykinin on the ischaemic heart: implication of the B1 receptor. *Br. J. Pharmacol*. **108**(2): 318-322.

Chai KX, Ni A, Wang D, Ward DC, Chao J, Chao L. (1996). Genomic DNA sequence, expression, and chromosomal localization of the human B1 bradykinin receptor gene BDKRB1. *Genomics*. **31**: 51-57.

Chao J, Chao L. (1988). Identification of a latent tissue Kallikrein, prolactin and growth hormone secretion in GH3 pituitary cells using modified radioimmuno-assays. *Mol. Cell. Endocrinol*. **55**: 21-31.

Chao C, Madeddu P, Wang C, Liang Y, Chao L, Chao J. (1996). Differential regulation of kallikrein, kininogen, and kallikrein-binding protein in arterial hypertensive rats. *Am. J. Physiol*. **271**(1 Pt 2): F78-86.

Chen S, Khan ZA, Cukiernik M, Chakrabarti S. (2003). Differential activation of NF-kappa B and AP-1 in increased fibronectin synthesis in target organs of diabetic complications. *Am. J. Physiol. Endocrinol. Metab.* **284**(6): E1089-1097.

Cheng CP, Onishi K, Ohte N, Suzuki M, Little WC. (1998). Functional effects of endogenous bradykinin in congestive heart failure. *J. Am. Coll. Cardiol.* **31**(7): 1679-1686.

Christopher J, Velarde V, Zhang D, Mayfield D, Mayfield RK, Jaffa AA. (2001). Regulation of B(2)-kinin receptors by glucose in vascular smooth muscle cells. *Am. J. Physiol. Heart Circ. Physiol.* **280**(4): H1537-1546.

Christopher J, Jaffa AA. (2002). Diabetes modulates the expression of glomerular kinin receptors. *Int. Immunopharmacol.* **2**(13-14): 1771-1779.

Church GM, Gilbert W. (1984). Genomic sequencing. *Proc. Natl. Acad. Sci. USA.* **89**: 1991-1995.

Cleutjens JPM, Blankesteyn WM, Daemen MJ, Smits JF. (1999). The infarcted myocardium: simply dead tissue, or a lively target for therapeutic interventions. *Cardiovasc. Res.* **44**(2): 232-241.

Cloutier F, Couture R. (2000). Pharmacological characterization of the cardiovascular responses elicited by kinin B(1) and B(2) receptor agonists in the spinal cord of streptozotocin-diabetic rats. *Br. J. Pharmacol.* **130**(2): 375-385.

Cohen RA. (1993). Dysfunction of vascular endothelium in diabetes mellitus. *Circulation.* **87**(sV): V67-V76.

Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, Oliveiras-Santos AJ, da Costa J, Zhang L, Pei Y, Scholey J, Ferrario CM, Manoukian AS, Chappell MC, Backx PH, Yagil Y, Penninger JM. (2002). Angiotensin-converting enzyme 2 is an essential regulator of heart function. *Nature.* **417**(6891): 822-828.

Curnow KM, Pascoe L, Davies E, White PC, Corvol P, Clauser E. (1993). Alternatively spliced human type 1 angiotensin II receptor mRNAs are translated at different efficiencies and encode two receptor isoforms. *Mol. Endocrinol.* **9**(9): 1250-1265.

Danckwardt L, Shimizu I, Bonner G, Rettig R, Unger T. (1990). Converting enzyme inhibition in kinin-deficient brown Norway rats. *Hypertension.* **16**(4): 429-435.

Damas J. (1996). The brown Norway rats and the kinin system. *Peptides.* **17**(5): 859-872.

Davis AJ, Perkins MN. (1994). The involvement of bradykinin B1 and B2 receptor mechanisms in cytokine-induced mechanical hyperalgesia in the rat. *Br. J. Pharmacol.* **113**(1): 63-68.

Davis TN. (1992). What's new with calcium? *Cell.* **71**: 557-564.

de Blois D, Bouthillier J, Marceau F. (1991). Pulse exposure to protein synthesis inhibitors enhances vascular responses to des-Arg9-bradykinin: possible role of interleukin-1. *Br. J. Pharmacol.* **103**(1): 1057-1066.

deBlois D, Drapeau G, Petitclerc E, Marceau F. (1992). Synergism between the contractile effect of epidermal growth factor and that of des-Arg9-bradykinin or of alpha-thrombin in rabbit aortic rings. *Br. J. Pharmacol.* **105**(4): 959-967.

Dean R, Murone C, Lew RA, Zhuo J, Casley D, Muller-Esterl W, Alcorn D, Mendelsohn FA. (1997). Localization of bradykinin B2 binding sites in rat kidney following chronic ACE inhibitor treatment. *Kidney Int.* **52**(5): 1261-1270.

Deddish PA, Marcic B, Jackman HL, Wang HZ, Skidgel RA, Erdös EG. (1998). N-domain-specific substrate and C-domain inhibitors of angiotensin-converting enzyme: angiotensin-(1-7) and keto-ACE. *Hypertension.* **31**(4): 912-917.

Dedio J, Wiemer G, Rutten H, Dendorfer A, Schölkens BA, Müller-Esterl W, Wohlfart P. (2001). Tissue kallikrein KLK1 is expressed *de novo* in endothelial cells and mediates relaxation of human umbilical veins. *Biol. Chem.* **382**(10): 1483-1490.

de Gasparo M, Siragy HM. (1999). The AT2 receptor: fact, fancy and fantasy. *Regul. Pept.* **81**(1-3): 11-24.

de Jager T, Pelzer T, Muller-Botz S, Imam A, Muck J, Neyses L. (2001). Mechanisms of estrogen receptor action in the myocardium. Rapid gene activation via the ERK1/2 pathway and serum response elements. *J. Biol. Chem.* **276**(30): 27873-27880.

Dendorfer A, Wolfrum S, Dominiak P. (1999). Pharmacology and cardiovascular implications of the kinin-kallikrein system. *Jpn. J. Pharmacol.* **79**(4): 403-426.

Derkx FH, Schalekamp MP, Schalekamp MA. (1987). Two-step prorenin-renin conversion. Isolation of an intermediary form of activated prorenin. *J. Biol. Chem.* **262**(6): 2472-2477.

Dhalla NS, Liu X, Panagia V, Takeda N. (1998). Subcellular remodeling and heart dysfunction in chronic diabetes. *Cardiovasc. Res.* **40**(2): 239-247.

Diamandis EP, Yousef GM. (2002). Human tissue kallikreins: a family of new cancer biomarkers. *Clin. Chem.* **48**(8): 1198-1205.

Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of the OPTIMAAL Study Group. (2002). Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial in Myocardial Infarction with Angiotensin II Antagonist Losartan. *Lancet*. **360**(9335): 752-760.

Dietze G, Wicklymayr M, Mayer L. (1997). Evidence for a participation of the kallikrein-kinin system in the regulation of muscle metabolism during hypoxia. *Hoppe Seylers Z. Physiol. Chem.* **358**(6): 633-638.

Dimitropoulou C, White RE, Fuchs L, Zhang H, Catravas JD, Carrier GO. (2001). Angiotensin II relaxes microvessels via the AT(2) receptor and Ca(2+)-activated K(+) (BK(Ca)) channels. *Hypertension*. **37**(2): 301-307.

Dixon BS, Dennis MJ. (1999). Regulation of mitogenesis by kinins in arterial smooth muscle cells. *Am. J. Physiol.* **273**(1 Pt 1): C7-20.

Dixon IM, Kaneko M, Hata T, Panagia V, Dhalla NS. (1990). Alterations in cardiac membrane Ca²⁺ transport during oxidative stress. *Mol. Cell. Biochem.* **99**(2): 125-133.

Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, Donovan M, Woolf B, Robison K, Jeyaseelan R, Breitbart RE, Acton S. (2000). A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. *Circ. Res.* **87**(5): E1-9.

Duka I, Duka A, Kintsurashvili E, Johns C, Gavras I, Gavras H. (2003). Mechanisms mediating the vasoactive effects of the B1 receptors of bradykinin. *Hypertension*. **42**(5): 1021-1025.

Duka I, Kintsurashvili E, Gavras I, Johns C, Bresnahan M, Gavras H. (2001). Vasoactive potential of the b(1) bradykinin receptor in normotension and hypertension. *Circ. Res.* **88**(3): 275-281.

Duncan AM, Burrell LM, Kladis A, Campbell DJ. (1996). Effects of angiotensin-converting enzyme inhibition on angiotensin and bradykinin peptides in rats with myocardial infarction. *J. Cardiovasc. Pharmacol.* **28**(6): 746-754.

Eggerickx D, Raspe E, Bertrand D, Vassart G, Parmentier M. (1992). Molecular cloning, functional expression and pharmacological characterization of a human bradykinin B2 receptor gene. *Biochem. Biophys. Res. Commun.* **187**(3): 1306-1133.

El-Dahr SS, Harrison-Bernard LM, Dipp S, Yosipiv IV, Meleg-Smith S. (2000). Bradykinin B2 null mice are prone to renal dysplasia: gene-environment interactions in kidney development. *Physiol. Genomics.* **3**(3): 121-131.

Emanuelli C, Maestri R, Corradi D, Marchione R, Minasi A, Tozzi MG, Salis MB, Straino S, Capogrossi MC, Olivetti G, Madeddu P. (1999). Dilated and failing cardiomyopathy in bradykinin B(2) receptor knockout mice. *Circulation*. **100**(23): 2359-2365.

Emanuelli C, Salis MB, Pinna A, Stacca T, Milia AF, Spano A, Chao J, Chao L, Sciola L, Madeddu P. (2002). Prevention of diabetes-induced microangiopathy by human tissue kallikrein gene transfer. *Circulation*. **106**(8): 993-999.

Endo Y, Arima S, Yaoita H, Tsunoda K, Omata K, Ito S. (1998). Vasodilation mediated by angiotensin II type 2 receptor is impaired in afferent arterioles of young spontaneously hypertensive rats. *J. Vasc. Res.* **35**(6): 421-427.

Erdös EG. (1990). Some old and some new ideas on kinin metabolism. *J. Cardiovasc. Pharmacol.* **15**(s6): 20-24.

Erdös EG, Marcic BM. (2001). Kinins, receptors, kininases and inhibitors--where did they lead us?. *Biol. Chem.* **382**(1): 43-47.

Erdös EG, Skidgel RA. (1989). Neutral Endopeptidase 24.11 (ekephalinase) and related regulators of peptide hormones. *FASEB.* **3**(2): 145-151.

Erdös EG, Skidgel RA. (1997). Metabolism of bradykinin by peptidases in health and disease. In: *The Kinin System*. Edited by Farmer SG. *New York: Academic*: 112-139.

Erdös EG, Yang HY. (1967). An enzyme in microsomal fraction of kidney that inactivates bradykinin. *Life. Sci.* **6**(6): 569-574.

Fabris B, Jackson B, Kohzuki M, Perich R, Johnston CI. (1990). Increased cardiac angiotensin-converting enzyme in rats with chronic heart failure. *Clin. Exp. Pharmacol. Physiol.* **17**(4): 309-314.

Falkenhahn M, Franke F, Bohle RM, Zhu YC, Stauss HM, Bachmann S, Danilov S, Unger T. (1995). Cellular distribution of angiotensin-converting enzyme after myocardial infarction. *Hypertension*. **25**(2): 219-226.

Farmer SG, Powell SJ, Wilkins DE, Graham A. (1998). Cloning, sequencing and functional expression of a guinea pig lung Bradykinin B2 receptor. *Eur. J. Pharmacol.* **346**(2-3): 291-298.

Faussner A, Bathon JM, Proud D. (1999). Comparison of the responses of B1 and B2 kinin receptors to agonist stimulation. *Immunopharmacology*. **45**(1-3): 13-20.

Faussner A, Heinz-Erian P, Klier C, Roscher AA. (1991). Solubilization and characterization of B2 bradykinin receptors from cultured human fibroblasts. *J. Biol. Chem.* **266**(15): 9442-9446.

Faussner A, Proud D, Towns M, Bathon JM. (1998). Influence of the cytosolic carboxyl termini of human B1 and B2 kinin receptors on receptor sequestration, ligand internalization, and signal transduction. *J. Biol. Chem.* **273**(5): 2617-2623.

Ferrario CM, Iyer SN. (1998). Angiotensin-(1-7): a bioactive fragment of the renin-angiotensin system. *Regul. Pept.* **78**(1-3): 13-18.

Ferreira AJ, Santos RA, Almeida AP. (2001). Angiotensin-(1-7): cardioprotective effect in myocardial ischemia/reperfusion. *Hypertension.* **38**(3 Pt 2): 665-668.

Figueras C, Maciver AG, Mackenzie JC. (1988). Localisation of immunoreactive Kininogen and tissue Kallikrein in the human nephron. *Histochemistry.* **89**: 437-442.

Forth W, Henschler D, Rummel W. (2001). Allgemeine und spezielle Pharmakologie und Toxikologie. *Urban & Fischer München-Jena.*

Foucart S, Grondin L, Couture R, Nadeau R. (1997). Modulation of noradrenaline release by B1 and B2 kinin receptors during metabolic anoxia in the rat isolated atria. *Can. J. Physiol. Pharmacol.* **75**(6): 639-645.

Frangogiannis NG, Smith CW, Entman ML. (2002). The inflammatory response in myocardial infarction. *Cardiovasc Res.* **53**(1): 31-47.

Frankton S, Harvey CB, Gleason LM, Fadel A, Williams GR. (2004). Multiple messenger ribonucleic acid variants regulate cell-specific expression of human thyroid hormone receptor β 1. *Mol. Endocrinol.* **18**(7): 1631-1642.

Frantz S, Fraccarollo D, Wagner H, Behr TM, Jung P, Angermann CE, Ertl G, Bauersachs J. (2003). Sustained activation of nuclear factor kappa B and activator protein 1 in chronic heart failure. *Cardiovasc. Res.* **57**(3): 749-756.

Freeman EJ, Chisolm GM, Ferrario CM, Tallant EA. (1996). Angiotensin-(1-7) inhibits vascular smooth muscle cell growth. *Hypertension.* **28**(1): 104-108.

Frey EK. (1926). Zusammenhänge zwischen Herzarbeit und Nierentätigkeit. *Arch. Klin. Chir.* **142**: 633-669.

Frey EK, Kraut H. (1928). Ein neues Kreislaufhormon und seine Wirkung. *Arch. Exp. Pathol. Pharmacol.* **133**: 1-5.

Frey EK, Kraut H, Werle E. (1988). Das Kallikrein-Kinin-System und seine Inhibitoren. *Enke-Verlag, Stuttgart.*

Friis UG, Jensen BL, Sethi S, Andreasen D, Hansen PB, Skott O. (2002). Control of renin secretion from rat juxtaglomerular cells by cAMP-specific phosphodiesterases. *Circ. Res.* **90**(9): 996-1003.

Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A, Nadal-Ginard B, Anversa P. (2000). Myocardial cell death in human diabetes. *Circ. Res.* **87**(12): 1123-1132.

Fujii M, Wada A, Tsutamoto T, Ohnishi M, Isono T, Kinoshita M. (2002). Bradykinin improves left ventricular diastolic function under long-term angiotensin-converting enzyme inhibition in heart failure. *Hypertension.* **39**(5): 952-957.

Fujiwara Y, Mantione CR, Yamamura HI. (1988). Identification of B2 bradykinin binding sites in guinea-pig brain. *Eur. J. Pharmacol.* **147**(3): 487-488.

Gafford JT, Skidgel RA, Erdös EG, Hersh LB. (1983). Human kidney "enkephalinase", a neutral metalloendopeptidase that cleaves active peptides. *Biochemistry.* **22**(13): 3265-3271.

Gainer JV, Brown NJ, Bachvarova M, Bastien L, Maltais I, Marceau F, Bachvarov DR. (2000). Altered frequency of a promoter polymorphism of the kinin B2 receptor gene in hypertensive African-Americans. *Am. J. Hypertens.* **13**(12): 1268-1273.

Gainer JV, Morrow JD, Loveland A, King DJ, Brown NJ. (1998). Effect of bradykinin-receptor blockade on the response to angiotensin-converting-enzyme inhibitor in normotensive and hypertensive subjects. *N. Engl. J. Med.* **339**(18): 1285-1292.

Gerken VM, Santos RA. (1992). Centrally infused bradykinin increases baroreceptor reflex sensitivity. *Hypertension.* **19**(s2): 1176-181.

Gohlke P, Linz W, Schölkens BA, Kuwer I, Bartenbach S, Schnell A, Unger T. (1994). Angiotensin-converting enzyme inhibition improves cardiac function. Role of bradykinin. *Hypertension.* **23**(4): 411-418.

Gohlke P, Pees C, Unger T. (1998). AT2 receptor stimulation increases aortic cyclic GMP in SHRSP by a kinin-dependent mechanism. *Hypertension.* **31**(1 Pt 2): 349-355.

Gordon C, Rempher KJ. (2003). Brain (B-type) natriuretic peptide: implications for heart failure management. *AACN Clin. Issues.* **14**(4): 532-542.

Gosele C, Grutzner F, Pesquero JB, Silva JA Jr, Junge T, Ganten D, Bader M, Knoblauch M. (2000). Assignment of the kinin receptor B1 and B2 genes (Bdkrb1 and Bdkrb2) to rat chromosome 6q3.2 by FISH and radiation hybrid mapping. *Cytogenet. Cell Genet.* **89**(1-2): 51-52.

Grohe C, Kahlert S, Lobbert K, Stimpel M, Karas RH, Vetter H, Neyses L. (1997). Cardiac myocytes and fibroblasts contain functional estrogen receptors. *FEBS Lett.* **416**(1): 107-112.

- Gross R, Schölmerich P, Gerok W. (1987).** Lehrbuch der inneren Medizin. *Schattauer, Stuttgart.* 251-418.
- Gross V, Milia AF, Plehm R, Inagami T, Luft FC. (2000).** Long-term blood pressure telemetry in AT2 receptor-disrupted mice. *J. Hypertens.* **J18(7):** 955-961.
- Grossman E, Messerli FH. (1996).** Diabetic and hypertensive heart disease. *Ann. Intern. Med.* **125(4):** 304-310.
- Groves P, Kurz S, Just H, Drexler H. (1995).** Role of endogenous bradykinin in human coronary vasomotor control. *Circulation.* **92(12):** 3424-30.
- Guan H, Cachofeiro V, Pucci ML, Kaminski PM, Wolin MS, Nasjletti A. (1996).** Nitric oxide and the depressor response to angiotensin blockade in hypertension. *Hypertension.* **27(1):** 19-24.
- Guillen I, Blanes M, Gomez-Lechon MJ, Castell JV. (1995).** Cytokine signaling during myocardial infarction: sequential appearance of IL-1 beta and IL-6. *Am. J. Physiol.* **269(2 Pt 2):** R229-235.
- Gurrath M. (2001).** Peptide-binding G protein-coupled receptors: new opportunities for drug design. *Curr. Med. Chem.* **8(13):** 1257-1299.
- Gutkind JS, Novotny EA, Brann MR, Robbins KC. (1991).** Muscarinic acetylcholine receptor subtypes as agonist-dependent oncogenes. *Proc. Natl. Acad. Sci. U S A.* **88(11):** 4703-4707.
- Ha H, Dunham EW. (1987).** Limited capacity for renal vasodilatation in anesthetized diabetic rats. *Am. J. Physiol.* **253(4Pt2):** H845-855.
- Hall MH. (1997).** Bradykinin receptors. *Gen. Pharmac.* **28(1):** 1-6.
- Hall, JM, Morton, KM. (1997).** The pharmacology and Immunopharmacology of kinin receptors. The Kinin System. *Academic Press, London:* 9–43.
- Harrison TR, Braunwald E, Fauci AS, Hauser K, Kasper DL, Longo E. (2001).** Harrison's Principles of Internal Medicine (15th edition). *McGraw-Hill Publishing Company.*
- Hartl WH, Jauch KW, Wolfe RR, Schildberg FW. (1990).** Effects of kinins on glucose metabolism *in vivo*. *Horm. Metab. Res. Suppl.* **22:** 79-84.
- Hashimoto K, Hamamoto H, Honda Y, Hirose M, Fukukawa S, Kimura E. (1978).** Changes in components of kinin system and hemodynamic in acute myocardial infarction. *Am. Heart. J.* **95(5):** 619-626.

- Hashimoto K, Hirose M, Furukawa S, Hayakawa H, Kimura E. (1977).** Changes in hemodynamics and bradykinin concentration in coronary sinus blood in experimental coronary artery occlusion. *Jpn. Heart. J.* **18**(5): 679-689.
- Hecker M, Blaukat A, Bara AT, Müller-Esterl W, Busse R. (2003).** ACE inhibitor potentiation of bradykinin-induced vasoconstriction. *Br. J. Pharmacol.* **121**(7): 1475-1481.
- Hecker M, Porsti I, Bara AT, Busse R. (1994).** Potentiation by ACE inhibitors of the dilator response to bradykinin in the coronary microcirculation: interaction at the receptor level. *Br. J. Pharmacol.* **111**(1): 238-244.
- Heilig R, Petit JL, Vico V, Dasilva C, Robert C, Wincker P, Brottier P, Cattolico L, Barbe V, Pelletier E, Artiguenave F, Levy M, Eckenberg R, Bruls T, deBerardinis V, Cruaud C, Gyapay G, Saurin W, Weissenbach J. (2001).** Sequencing of the human chromosome 14. Unpublished *NCBI Acc*: AL355102.
- Hein L, Barsh GS, Pratt RE, Dzau VJ, Kobilka BK. (1995).** Behavioural and cardiovascular effects of disrupting the angiotensin II type-2 receptor in mice. *Nature.* **377**(6551): 744-747.
- Helliwell PA, Richardson M, Affleck J, Kellett GL. (2000).** Regulation of GLUT5, GLUT2 and intestinal brush-border fructose absorption by the extracellular signal-regulated kinase, p38 mitogen-activated kinase and phosphatidylinositol 3-kinase intracellular signalling pathways: implications for adaptation to diabetes. *Biochem. J.* **350**(Pt 1): 163-169.
- Herr RR, Eble TE, Bergy ME, Jahnke HK. (1959-1960).** Isolation and characterization of streptozotocin. *Antibiot. Annu.* **7**: 236-240.
- Hess JF, Borkowski JA, Stonesifer GY, MacNeil T, Strader CD, Ransom RW. (1994a).** Cloning and pharmacological characterization of bradykinin receptors. *Braz. J. Med. Biol. Res.* **27**(8): 1725-1731.
- Hess JF, Borkowski JA, Young GS, Strader CD, Ransom RW. (1992).** Cloning and pharmacological characterization of a human bradykinin (BK-2) receptor. *Biochem. Biophys. Res. Commun.* **184**(1): 260-268.
- Hess JF, Derrick AW, MacNeil T, Borkowski JA. (1996).** The agonist selectivity of a mouse B1 bradykinin receptor differs from human and rabbit B1 receptors. *Immunopharmacology.* **33**(1-3): 1-8.
- Hess JF, Hey PJ, Chen TB, O'Brien J, Omalley SS, Pettibone DJ, Chang RS. (2001).** Molecular cloning and pharmacological characterization of the canine B1 and B2 bradykinin receptors. *Biol. Chem.* **382**(1): 123-129.

Hess JF, Hey PJ, Chen TB, Pettibone DJ, Chang RS. (2002). Molecular and pharmacological diversity of the kinin B1 receptor. *Int. Immunopharmacol.* **2**(13-14): 1747-1754.

Hess JF, Borkowski JA, Macneil T, Stonesifer GY, Fraher J, Strader CD, Ransom RW. (1994b). Differential pharmacology of cloned human and mouse B2 bradykinin receptors. *Mol. Pharmacol.* **45**(1): 1-8.

Higashimori K, Zhao Y, Higaki J, Kamitani A, Katsuya T, Nakura J, Miki T, Mikami H, Ogihara T. (1993). Association analysis of a polymorphism of the angiotensin converting enzyme gene with essential hypertension in the Japanese population. *Biochem. Biophys. Res. Commun.* **191**(2): 399-404.

Hofmann KP, Ernst OP. (2001). To see from light--biophysics of visual signal transduction. *Z. Med. Phys.* **11**(4): 217-225.

Hoffmann S, Krause T, Pinto Y, Buikema H, Bohlender J, Nishimura H, Inagami T, Ganten D, Urata H. (1996). Cardiac-specific expression of the human AT₁ receptor in transgenic rats. *Hypertension.* **28**(p76): 535.

Hoffmann S, Krause T, van Geel PP, Willenbrock R, Pagel I, Pinto YM, Buikema H, van Gilst WH, Lindschau C, Paul M, Inagami T, Ganten D, Urata H. (2001). Overexpression of the human angiotensin II type 1 receptor in the rat heart augments load induced cardiac hypertrophy. *J. Mol. Med.* **79**(10): 601-608.

Holmes SJ, Espiner EA, Richards AM, Yandle TG, Frampton C. (1993). Renal, endocrine, and hemodynamic effects of human brain natriuretic peptide in normal man. *J. Clin. Endocrinol. Metab.* **76**(1): 91-96.

Holzner JH, Mathes P. (1982). Atlas der Herzerkrankungen. *Pharmazeutische Verlagsgesellschaft, München:* 156-162.

Hornig B, Kohler C, Drexler H. (1997). Role of bradykinin in mediating vascular effects of angiotensin-converting enzyme inhibitors in humans. *Circulation.* **95**(5): 1115-1118.

Hosenpud JD, Campbell SM, Mendelson DJ. (1989). Interleukin-1-induced myocardial depression in an isolated beating heart preparation. *J. Heart Transplant.* **8**(6): 460-464.

Houel R, Su J, Barbe F, Choussat R, Crozatier B, Hittinger L. (1997). Regional myocardial effects of intracoronary bradykinin in conscious dogs. *Am. J. Physiol.* **272**(3 Pt 2): H1266-1274.

Hu K, Gaudron P, Anders HJ, Weidemann F, Turschner O, Nahrendorf M, Ertl G. (1998). Chronic effects of early started angiotensin converting enzyme inhibition and angiotensin AT₁-receptor subtype blockade in rats with myocardial infarction: role of bradykinin. *Cardiovasc. Res.* **39**(2): 401-412.

Hummerich W, Feltkamp H, Konrads A, Ahlmann P, Bornhofen H. (1979). Renin-activation by kallikrein: evidence for alkaline-activation of plasma renin. *Eur. J. Clin. Invest.* **9**(6): 447-449.

Ichihara S, Senbonmatsu K, Price E, Ichiki T, Gaffney A, Inagami T (2001). Angiotensin II type 2 receptor is essential for left ventricular hypertrophy and cardiac fibrosis in chronic angiotensin II-induced hypertension. *Circulation.* **104**: 346-351.

Ichiki T, Labosky PA, Shiota C, Okuyama S, Imagawa Y, Fogo A, Niimura F, Ichikawa I, Hogan BL, Inagami T. (1995). Effects on blood pressure and exploratory behaviour of mice lacking angiotensin II type-2 receptor. *Nature.* **377**(6551): 748-750.

Igarashi M, Wakasaki H, Takahara N, Ishii H, Jiang ZY, Yamauchi T, Kuboki K, Meier M, Rhodes CJ, King GL. (1999). Glucose or diabetes activates p38 mitogen-activated protein kinase via different pathways. *J. Clin. Invest.* **103**(2): 185-195.

Ignjatovic T, Tan F, Brovkovich V, Skidgel RA, Erdös EG. (2002). Activation of bradykinin B1 receptor by ACE inhibitors. *Int. Immunopharmacol.* **2**(13-14): 1787-1793.

Ishigai Y, Mori T, Ikeda T, Fukuzawa A, Shibano T. (1997). Role of bradykinin-NO pathway in prevention of cardiac hypertrophy by ACE inhibitor in rat cardiomyocytes. *Am. J. Physiol.* **273**(6 Pt 2): H2659-2663.

Israel A, Cierco M, Sosa B. (2000). Angiotensin AT(2) receptors mediate vasodepressor response to footshock in rats. Role of kinins, nitric oxide and prostaglandins. *Eur. J. Pharmacol.* **394**(1): 103-108.

Ito H, Izumi H, Tohru I, Masataka M. (2003). Bradykinin inhibits development of myocardial infarction through B2 receptor signalling by increment of regional blood flow around the ischaemic lesions in rats. *Brit. J. Pharmacol.* **138**(1): 225-233.

Ito M, Oliverio MI, Mannon PJ, Best CF, Maeda N, Smithies O, Coffman TM. (1995). Regulation of blood pressure by the type 1A angiotensin II receptor gene. *Proc. Natl. Acad. Sci. U S A.* **92**(8): 3521-3525.

Iwai N, Matsunaga M, Kita T, Tei M, Kawai C. (1988). Detection of low molecular Kininogen messenger RNA in human kidney. *J.Hypertens.* **6**(s): 399-400.

Iwai N, Ohmichi N, Nakamura Y, Kinoshita M. (1994). DD genotype of the angiotensin-converting enzyme gene is a risk factor for left ventricular hypertrophy. *Circulation.* **90**(6): 2622-2628.

Jacobs M, Staufenberger S, Gergs U, Meuter K, Brandstätter K, Hafner M, Ertl G, Schorb W. (1999). Tumor necrosis factor- α at acute myocardial infarction in rats and effects on cardiac fibroblasts. *J. Mol. Cell Cardiol.* **31**(11): 1949-1959.

Jaffa AA, Rust PF, Mayfield RK. (1995). Kinin, a mediator of diabetes-induced glomerular Hyperfiltration. *Diabetes*. **44**(2): 156-160.

Jiang H, Lucy MC. (2001). Variants of the 5'-untranslated region of the bovine growth hormone receptor mRNA: Isolation, expression and effects on translational efficiency. *Gene*. **265**(3): 45-53.

Jones C, Phillips E, Davis C, Arbuckle J, Yaqoob M, Burgess GM, Docherty RJ, Webb M, Bevan SJ, McIntyre P. (1999). Molecular characterisation of cloned bradykinin B1 receptors from rat and human. *Eur. J. Pharmacol.* **374**(3): 423-33.

Ju H, Zhao S, Jassal DS, Dixon IMC. (1997). Effect of AT1 receptor blockade on cardiac collagen remodeling after myocardial infarction. *Cardiovasc. Res.* **35**(2): 223-232.

Julius D, Livelli TJ, Jessell TM, Axel R. (1989). Ectopic expression of the serotonin 1c receptor and the triggering of malignant transformation. *Science*. **244**(4908): 1057-1062.

Kagiyama S, Eguchi S, Frank GD, Inagami T, Zhang YC, Phillips MI. (2002). Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense. *Circulation*. **106**(8): 909-912.

Kammerer S, Braun A, Arnold N, Roscher AA. (1995). The human bradykinin B2 receptor gene: full length cDNA, genomic organization and identification of the regulatory region. *Biochem. Biophys. Res. Commun.* **211**(1): 226-233.

Kannel WB, Hjortland M, Castelli WP. (1974). Role of diabetes in congestive heart failure: the Framingham study. *Am. J. Cardiol.* **34**(1): 29-34.

Karin M, Ben-Neriah Y. (2000). Phosphorylation meets ubiquitination: the control of NF-kappaB activity. *Annu. Rev. Immunol.* **18**: 621-663.

Karlson P, Doenecke D, Koolman J. (1994). Biochemie. *Georg Thieme Verlag, Stuttgart*: 332-344.

Katada J, Majima M. (2002). AT(2) receptor-dependent vasodilation is mediated by activation of vascular kinin generation under flow conditions. *Br. J. Pharmacol.* **136**(4): 484-491.

Keravis TM, Nehlig H, Delacroix MF, Regoli D, Hiley CR, Stoclet JC. (1991). High-affinity bradykinin B2 binding sites sensitive to guanine nucleotides in bovine aortic endothelial cells. *Eur. J. Pharmacol.* **207**(2): 149-155.

Kikkawa Y, Yamanaka N, Tada J, Kanamori N, Tsumura K, Hosoi K. (1998). Prorenin processing and restricted endoproteolysis by mouse tissue kallikrein family enzymes (mK1, mK9, mK13, and mK22). *Biochim. Biophys. Acta.* **1382**(1): 55-64.

Kim NN, Villegas S, Summerour SR, Villarreal FJ. (1999). Regulation of cardiac fibroblast extracellular matrix production by Bradykinin and nitric oxide. *J. Mol. Cell. Cardiol.* **31**(2): 457-466.

Kim S, Yoshiyama M, Izumi Y, Kawano H, Kimoto M, Zhan Y, Iwao H. (2001). Effects of combination of ACE inhibitor and angiotensin receptor blocker on cardiac remodeling, cardiac function, and survival in rat heart failure. *Circulation.* **103**(1): 148-154.

Kim WS, Nakayama K, Nakagawa T, Kawamura Y, Haraguchi K, Murakami K. (1991). Mouse submandibular gland prorenin-converting enzyme is a member of glandular kallikrein family. *J. Biol. Chem.* **266**(29): 19283-19287.

Kimura E, Hashimoto K, Furukawa S, Hayakawa H. (1973). Changes in bradykinin level in coronary sinus blood after the experimental occlusion of a coronary artery. *Am. Heart. J.* **85**(5): 635-647.

Kintsurashvili E, Duka I, Gavras I, Johns C, Farmakiotis D, Gavras H. (2001). Effects of ANG II on bradykinin receptor gene expression in cardiomyocytes and vascular smooth muscle cells. *Am. J. Physiol. Heart Circ. Physiol.* **281**(4): H1778-1783.

Klein I, Levey JS, Gondek M. (1982). Characterization of the phosphoprotein profile in spontaneously beating cultured rat heart cells. *Proc. Soc. Exp. Biol. Med.* **170**(1): 19-24.

Koch M, Wendorf M, Dendorfer A, Wolfrum S, Schulze K, Spillmann F, Schultheiss HP, Tschöpe C. (2003). Cardiac kinin level in experimental diabetes mellitus: Role of kininases. *Am. J. Physiol. Heart Circ. Physiol.* **285**(1): H418-423.

Kozak M. (1989). Circumstances and mechanisms of inhibition of translation by secondary structure in eucaryotic mRNAs. *Mol. Cell Biol.* **9**(11): 5134-5142.

Kozak M. (1991). An analysis of vertebrate mRNA sequences; intimations of translational control. *Mol. Cell Biol.* **11**(4): 887-903.

Kraut H, Frey EK, Werle E. (1930). Der Nachweis eines Kreislaufhormons in der Pankreasdrüse Hoppe-Seyler's. *Z. Physiol. Chem.* **189**: 97-106.

Kyle DJ, Martin JA, Burch RM, Carter JP, Lu SF, Meeker S, Prosser JC, Sullivan JP, Togo J, Noronha-Blob L, et al. (1991). Probing the bradykinin receptor: mapping the geometric topography using ethers of hydroxyproline in novel peptides. *J. Med. Chem.* **34**(8): 2649-2653.

Lagneux C, Bader M, Pesquero JB, Demenge P, Ribouot C. (2002). Detrimental implication of B1 receptors in myocardial ischemia: evidence from pharmacological blockade and gene knockout mice. *Int. Immunopharmacol.* **2**(6): 815-822.

Lamontagne D, König A, Bassenge E, Busse R. (1992). Prostacyclin and nitric oxide contribute to the vasodilator action of acetylcholine and bradykinin in the intact rabbit coronary bed. *J. Cardiovasc. Pharmacol.* **20**(4): 652-657.

Lamontagne D, Nadeau R, Adam A. (1995). Effect of enalaprilat on bradykinin and des-Arg⁹-bradykinin release following reperfusion of the ischaemic rat heart. *Br. J. Pharmacol.* **115**(3): 476-478.

Larivee P. (1998). Airway inflammation and remodelling in asthma: airway epithelial cells. *Can. Respir. J.* **5**(1): 51-52.

Larrivee JF, Bachvarov DR, Houle F, Landry J, Huot J, Marceau F. (1998). Role of the mitogen-activated protein kinases in the expression of the kinin B1 receptors induced by tissue injury. *J. Immunol.* **160**(3): 1419-1426.

Lavie CJ, Ventura HO, Messerli FH. (1992). Left ventricular hypertrophy. Its relationship to obesity and hypertension. *Postgrad. Med.* **91**(7): 131-132, 135-138, 141-143.

Lavie CJ, Ventura HO, Messerli FH. (1991). Regression of increased left ventricular mass by antihypertensives. *Drugs.* **42**(6): 945-961.

Lechleitner M, Koch T, Herold M, Dzien A, Hoppichler F. (2000). Tumour necrosis factor-alpha plasma level in patients with type 1 diabetes mellitus and its association with glycaemic control and cardiovascular risk factors. *J. Intern. Med.* **248**(1): 67-76.

Leeb-Lundberg LM, Kang DS, Lamb ME, Fathy DB. (2001). The human B1 bradykinin receptor exhibits high ligand-independent, constitutive activity. Roles of residues in the fourth intracellular and third transmembranen domains. *J. Biol. Chem.* **276**(12): 8785-8792.

Li P, Chappell MC, Ferrario CM, Brosnihan KB. (1997). Angiotensin-(1-7) augments bradykinin-induced vasodilation by competing with ACE and releasing nitric oxide. *Hypertension.* **29**(1 Pt 2): 394-400.

Liao JK, Homcy CJ. (1993). The G proteins of the G alpha i and G alpha q family couple the Bradykinin receptor to the release of endothelium-derived relaxing factor. *J. Clin. Invest.* **92**(5): 2168-2172.

Lindpaintner K, Lee M, Larson MG, Rao VS, Pfeffer MA, Ordovas JM, Schaefer EJ, Wilson AF, Wilson PW, Vasan RS, Myers RH, Levy D. (1996). Absence of association or genetic linkage between the angiotensin-converting-enzyme gene and left ventricular mass. *N. Engl. J. Med.* **334**(16): 1023-1028.

Linz W, Busch AE. (2003). Intervention in the renin-angiotensin and kallikrein-kinin systems. Pharmacologic basis of the action of ACE inhibitors. *Pharm. Unserer Zeit.* **32**(1): 18-22.

Linz DN, Garcia VF, Arya G, Hug G, Tombragel E, Landrigan E, Chuck G, Tsoras M, Ryan M, Ziegler MM. (1995). Weanling and adult rats differ in fatty acid and carnitine metabolism during sepsis. *J. Pediatr. Surg.* **30**(7): 959-966.

Linz W, Wiemer G, Gohlke P, Unger T, Schölkens BA. (1995). Contribution of kinins to the cardiovascular actions of angiotensin-converting enzyme inhibitors. *Pharmacol. Rev.* **47**(1): 25-49.

Linz W, Wohlfart P, Schölkens BA, Malinski T, Wiemer G. (1999). Interactions among ACE, kinins and NO. *Cardiovasc. Res.* **43**(3): 549-561.

Litwin SE, Raya TE, Peter GA, Daugherty S, Goldman S. (1990). Abnormal cardiac funktion in the Streptozotocin-diabetic rat. *J. Clin. Invest.* **86**(2): 481-488.

Liu YH, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, Carretero OA. (1997). Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors. *J. Clin. Invest.* **99**(8): 1926-1935.

Lochner W, Parratt JR. (1966). A comparison of the effects of locally and systemically administered kinins on coronary blood flow and myocardial metabolism. *Br. J. Pharmacol.* **26**(1): 17-26.

Lorell BH, Blase A, Carabello BA. (2000). Left ventricular hypertrophy: pathogenesis, detection, and prognosis. *Circulation.* **102**(4): 470-479.

Lowry SF. (1993). Cytokine mediators of immunity and inflammation. *Arch. Surg.* **128**(11): 1235-1241.

Lung CC, Chan EK, Zuraw BL. (1997). Analysis of an exon 1 polymorphism of the B2 bradykinin receptor gene and its transcript in normal subjects and patients with C1 inhibitor deficiency. *J. Allergy Clin. Immunol.* **99**(1 Pt 1): 134-146.

Ma JX, Wang DZ, Chao L, Chao J. (1994a). Cloning, sequence analysis and expression of the gene encoding the mouse bradykinin B2 receptor. *Gene.* **149**(2): 283-288.

Ma JX, Wang DZ, Ward DC, Chen L, Dessai T, Chao J, Chao L. (1994b). Structure and chromosomal localization of the gene (BDKRB2) encoding human bradykinin B2 receptor. *Genomics.* **23**(2): 362-369.

MacCarthy PA, Shah AM. (2000). Impaired endothelium-dependent regulation of ventricular relaxation in pressure-overload cardiac hypertrophy. *Circulation.* **101**(15): 1854-1860.

MacNeil T, Bierilo KK, Menke JG, Hess JF. (1995). Cloning and pharmacological characterization of a rabbit bradykinin B1 receptor. *Biochim. Biophys. Acta.* **1264**(2): 223-228.

Madeddu P, Emanuelli C, Maestri R, Salis MB, Minasi A, Capogrossi MC, Olivetti G. (2000). Angiotensin II type 1 receptor blockade prevents cardiac remodeling in bradykinin B(2) receptor knockout mice. *Hypertension.* **35**(1 Pt 2): 391-396.

Madeddu P, Emanuelli C, Song Q, Varoni MV, Demontis MP, Anania V, Glorioso N, Chao J. (1997). Regulation of bradykinin B2-receptor expression by oestrogen. *Br. J. Pharmacol.* **121**(8): 1763-9.

Madeddu P, Varoni MV, Palomba D, Emanuelli C, Demontis MP, Glorioso N, Dessi-Fulgheri P, Sarzani R, Anania V. (1998). Cardiovascular phenotype of a mouse strain with disruption of bradykinin B2-receptor gene. *Circulation.* **96**(10): 3570-3578.

Maestri R, Milia AF, Salis MB, Graiani G, Lagrasra C, Monica M, Corradi D, Emanuelli C, Madeddu P. (2003). Cardiac hypertrophy and microvascular deficit in kinin B2 receptor knockout mice. *Hypertension.* **41**(5): 1151-1155.

Mage M, Pecher C, Neau E, Cellier E, Dos Reiss ML, Schanstra JP, Couture R, Bascands JL, Girolami JP. (2002). Induction of B1 receptors in streptozotocin diabetic rats: possible involvement in the control of hyperglycemia-induced glomerular Erk 1 and 2 phosphorylation. *Can. J. Physiol. Pharmacol.* **80**(4): 328-333.

Mahabeer R, Bhoola KD. (2000). Kallikrein and kinin receptor genes. *Pharmacol. Ther.* **88**(1): 77-89.

Maisel AS, McCullough PA. (2003). Cardiac natriuretic peptides: a proteomic window to cardiac function and clinical management. *Rev. Cardiovasc. Med.* **4**(s4): S3-12.

Mann J, Sleight P. (2000). The HOPE Study. What does it contribute to general practice?. *MMW Fortschr. Med.* **142**(47): 28-32.

Marcic B, Deddish PA, Jackman HL, Erdös EG. (1999). Enhancement of bradykinin and resensitization of its B2 receptor. *Hypertension.* **33**(3): 835-843.

Marcic B, Deddish PA, Skidgel RA, Erdös EG, Minshall RD, Tan F. (2000). Replacement of the transmembrane anchor in angiotensin I-converting enzyme (ACE) with a glycosylphosphatidylinositol tail affects activation of the B2 bradykinin receptor by ACE inhibitors. *J. Biol. Chem.* **275**(21): 16110-16118.

Marceau B. (1995). Kinin B1 receptors: a review. *Immunopharmacology.* **30**(1): 1-26.

Marceau B, , Larrivee J-F, Bouthillier J, Bachvarova M, Hule S, Bachvarov DR. (1999). Effect of endogenous kinins, prostanoids, and NO on kinin B1 and B2 receptor expression in the rabbit. *Am. J. Physiol.* **227**: R15681-R1578.

Marceau F, Hess JF, Bachvarov DR. (1998). The B1 receptors for kinins. *Pharmacol. Rev.* **50**(3): 357-386.

Margolius HS. (1989). Tissue kallikreins and kinins: regulations and roles in hypertensive and diabetic diseases. *Annu. Rev. Pharmacol. Toxicol.* **29**: 343-364.

Margolius HS. (1996). Kallikreins and kinins molecular characteristics and cellular and tissue responses. *Diabetes.* **45**(s1): 14-19.

Marian AJ, Yu QT, Workman R, Greve G, Roberts R. (1993). Angiotensin-converting enzyme polymorphism in hypertrophic cardiomyopathy and sudden cardiac death. *Lancet.* **342**(8879): 1085-1086.

Marin-Castano ME, Schanstra JP, Neau E, Praddaude F, Pecher C, Ader JL, Girolami JP, Bascands JL. (2002). Induction of functional bradykinin b(1)-receptors in normotensive rats and mice under chronic Angiotensin-converting enzyme inhibitor treatment. *Circulation.* **105**(5): 627-632.

Marin-Castano ME, Schanstra JP, Praddaude F, Pesquero JB, Ader JL, Girolami JP, Bascands JL. (1998). Differential induction of functional B1-bradykinin receptors along the rat nephron in endotoxin induced inflammation. *Kidney Int.* **54**(6): 1888-1898.

Marinissen MJ, Gutkind JS. (2001). G-protein-coupled receptors and signaling networks: emerging paradigms. *Trends Pharmacol. Sci.* **22**(7): 368-376.

Martorana PA, Kettenbach B, Breipohl G, Linz W, Schölkens BA. (1990). Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist. *Eur. J. Pharmacol.* **182**(2): 395-396.

Mathis SA, Criscimagna NL, Leeb-Lundberg LM. (1996). B1 and B2 kinin receptors mediate distinct patterns of intracellular Ca²⁺ signaling in single cultured vascular smooth muscle cells. *Mol. Pharmacol.* **50**(1): 128-139.

Maruyama R, Hatta E, Yasuda K, Smith NC, Levi R. (2000). Angiotensin-converting enzyme-independent angiotensin formation in a human model of myocardial ischemia: modulation of norepinephrine release by angiotensin type 1 and angiotensin type 2 receptors. *J. Pharmacol. Exp. Ther.* **294**(1): 248-254.

Matsunami H, Montmayeur JP, Buck LB. (2000). A family of candidate taste receptors in human and mouse. *Nature.* **404**(6778): 601-604.

Maury CP und Teppo AM. (1989). Circulating tumour necrosis factor-alpha (cachectin) in myocardial infarction. *J Intern Med.* **225**(5): 333-336.

Mayfield RK, Shimojo N, Jaffa AA. (1996). Skeletal muscle kallikrein. Potential role in metabolic regulation. *Diabetes*. **45** (s1): S20-23.

McAllister BS, Leeb-Lundberg F, Olson MS. (1993). Bradykinin inhibition of EGF- and PDGF-induced DNA synthesis in human fibroblasts. *Am. J. Physiol.* **265**(2 Pt 1): C477-484.

McCormick RJ, Musch TI, Bergman BC, Thomas DP. (1994). Regional differences in LV collagen accumulation and mature cross-linking after myocardial infarction in rats. *Am. J. Physiol.* **266**(1 Pt 2): H354-359.

McDonald KM, Carlyle PF, Matthews J, Hauer K, Elbers T, Hunter D, Cohn JN. (1990). Early ventricular remodeling after myocardial damage and its attenuation by converting enzyme inhibition. *Trans. Assoc. Am. Physicians.* **103**: 229-235.

McDonald KM, Mock J, D'Aloia A, Parrish T, Hauer K, Francis G, Stillman A, Cohn JN. (1995). Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis. *Circulation.* **91**(7): 2043-2048.

McEachern AE, Shelton ER, Bhakta S, Obernolte R, Bach C, Zuppan P, Fujisaki J, Aldrich RW, Jarnagin K. (1991). Expression cloning of a rat B2 bradykinin receptor. *Proc. Natl. Acad. Sci. U S A.* **88**(17): 7724-7728.

McIntyre P, Phillips E, Skidmore E, Brown M, Webb M. (1993). Cloned murine bradykinin receptor exhibits a mixed B1 and B2 pharmacological selectivity. *Mol. Pharmacol.* **44**(2): 346-55.

McLean PG, Perretti M, Ahluwalia A. (1999). Inducible expression of the kinin B1 receptor in the endotoxemic heart: mechanisms of des-Arg9bradykinin-induced coronary vasodilation. *Br. J. Pharmacol.* **128**(2): 275-282.

McLean PG, Perretti M, Ahluwalia A. (2000). Kinin B(1) receptors and the cardiovascular system: regulation of expression and function. *Cardiovasc. Res.* **48**(2): 194-210.

Meffert S, Stoll M, Steckelings UM, Bottari SP, Unger T. (1996). The angiotensin II AT2 receptor inhibits proliferation and promotes differentiation in PC12W cells. *Mol. Cell. Endocrinol.* **122**(1): 59-67.

Menke JG, Borkowski JA, Bierilo KK, MacNeil T, Derrick AW, Schneck KA, Ransom RW, Strader CD, Linemeyer DL, Hess JF. (1994). Expression cloning of a human B1 bradykinin receptor. *J. Biol. Chem.* **269**(34): 21583-2156.

Milia AF, Gross V, Plehm R, De Silva JA Jr, Bader M, Luft FC. (2001). Normal blood pressure and renal function in mice lacking the bradykinin B(2) receptor. *Hypertension.* **37**(6): 1473-1479.

- Minshall RD, Tan F, Nakamura F, Rabito SF, Becker RP, Marcic B, Erdös EG. (1997).** Potentiation of the actions of bradykinin by angiotensin I-converting enzyme inhibitors. The role of expressed human bradykinin B2 receptors and angiotensin I-converting enzyme in CHO cells. *Circ. Res.* **81**(5): 848-856.
- Miric G, Dallemagne C, Endre Z, Margolin S, Taylor SM, Brown L. (2001).** Reversal of cardiac and renal fibrosis by pirfenidone and spironolactone in streptozocin-diabetic rats. *Br. J. Pharm.* **133**(5): 687-694.
- Miura S, Matsuo Y, Saku K. (2003).** Transactivation of KDR/Fik-1 by the B2 Receptor induces tube formation in human coronary endothelial cells. *Hypertension.* **41**(5): 1118-1123.
- Mizushige K, Yao L, Noma T, Kiyomoto H, Yu Y, Hosomi N, Ohmori K, Matsuo H. (2000).** Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. *Circulation.* **101**(8): 899-907.
- Morris BJ, McGirr JG. (1981).** Direct evidence, using Pro-Phe-ArgCH₂Cl, that plasma Kallikrein has a role in acid activation in inactive renin in plasma from normal subjects. *Biomed. Res.* **2**: 552-559.
- Müller-Esterl W. (1989).** Kininogens, kinins and kinships. *Thromb. Haemost.* **61**(1): 2-6.
- Müller-Esterl W, Iwanaga S, Nakanishi S. (1986).** Kininogens revisited. *Trends Biochem. Sci.* **11**(8): 336-339.
- Mukae S, Aoki S, Itoh S, Iwata T, Ueda H, Katagiri T. (2000).** Bradykinin B(2) receptor gene polymorphism is associated with angiotensin-converting enzyme inhibitor-related cough. *Hypertension.* **36**(1): 127-131.
- Mukae S, Itoh S, Aoki S, Iwata T, Nishio K, Sato R, Katagiri T. (2002).** Association of polymorphisms of the renin-angiotensin system and bradykinin B2 receptor with ACE-inhibitor-related cough. *J. Hum. Hypertens.* **16**(12): 857-863.
- Mullis KB, Faloona FA. (1987).** Specific synthesis of DNA *in vitro* via a polymerase catalysed chain reaction. *Methods Enzymol.* **155**: 335-350.
- Murohara T, Asahara T, Silver M, Bauters C, Masuda H, Kalka C, Kearney M, Chen D, Symes JF, Fishman MC, Huang PL, Isner JM. (1998).** Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. *J. Clin. Invest.* **101**(11): 2567-2578.

- Myerson SG, Montgomery HE, Whittingham M, Jubb M, World MJ, Humphries SE, Pennell DJ. (2001).** Left ventricular hypertrophy with exercise and ACE gene insertion/deletion polymorphism: a randomized controlled trial with losartan. *Circulation*. **103**(2): 226-30.
- Nahrendorf M, Hu K, Fraccarollo D, Hiller KH, Haase A, Bauer WR, Ertl G. (2003).** Time course of right ventricle remodeling in rats with experimental myocardial infarction. *Am. J. Physiol. Heart Circ. Physiol.* **284**(1): H241-248.
- Neumann FJ, Ott I, Gawaz M, Richardt G, Holzapfel H, Jochum M, Schömig A. (1995).** Cardiac release of cytokines and inflammatory responses in acute myocardial infarction. *Circulation*. **92**(4): 748-755.
- Neves FA, Duncan KG, Baxter JD. (1996).** Cathepsin B is a prorenin processing enzyme. *Hypertension*. **27**(3 Pt 2): 514-517.
- Ni A, Chai KX, Chao L, Chao J. (1998a).** Molecular cloning and expression of rat bradykinin B1 receptor. *Biochim. Biophys. Acta*. **1442**(2-3): 177-185.
- Ni A, Chao L, Chao J. (1998b).** Transcription factor nuclear factor kappa B regulates the inducible expression of the human B1 receptor gene in inflammation. *J. Biol. Chem.* **273**(5): 2784-2791.
- Nio Y, Matsubara H, Murasawa S, Kanasaki M, Inada M. (1995).** Regulation of gene transcription of angiotensin II receptor subtypes in myocardial infarction. *J. Clin. Invest.* **95**(1): 46-54.
- Nolly H, Carbini LA, Scicli G, Carretero OA, Scicli AG. (1994).** A local kallikrein-kinin system is present in rat hearts. *Hypertension*. **23**(6 Pt 2): 919-923.
- Nolly H, Scicli AG, Scicli G, Carretero OA. (1985).** Characterization of a kininogenase from rat vascular tissue resembling tissue kallikrein. *Circ. Res.* **56**(6): 816-821.
- Noutsias M, Pauschinger M, Ostermann K, Escher F, Blohm JH, Schultheiss H, Kühl U. (2002).** Digital image analysis system for the quantification of infiltrates and cell adhesion molecules in inflammatory cardiomyopathy. *Med. Sci. Monit.* **8**(5): MT59-71.
- Ody CE, Marinkovic DV, Hammon KJ, Stewart TA, Erdös EG. (1978).** Purification and properties of prolylcarboxypeptidase (angiotensinase C) from human kidney. *J. Biol. Chem.* **253**(17): 5927-31.
- Ohishi M, Rakugi H, Ogihara T. (1994).** Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. *N. Engl. J. Med.* **331**(16): 1097-1098.

Okusawa S, Gelfand JA, Ikejima T, Connolly RJ, Dinarello CA. (1988). Interleukin 1 induces a shock-like state in rabbits. Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. *J. Clin. Invest.* **81**(4): 1162-1172.

Ongali B, Campos MM, Bregola G, Rodi D, Regoli D, Thibault G, Simonato M, Couture R. (2003). Autoradiographic analysis of rat brain kinin B1 and B2 receptors: normal distribution and alterations induced by epilepsy. *J. Comp. Neurol.* **461**(4): 506-519.

Ono K, Matsumori A, Shioi T, Furukawa Y, Sasayama S. (1998). Cytokine gene expression after myocardial infarction in rat hearts: possible implication in left ventricular remodeling. *Circulation.* **98**(2): 149-156.

Opal SM, DePalo VA. (2000). Anti-inflammatory cytokines. *Chest.* **117**(4): 1162-1172.

Paegelow I, Werner H, Vietinghoff G, Wartner U. (1995). Release of cytokines from isolated lung strips by bradykinin. *Inflamm. Res.* **44**(7): 306-311.

Palik I, Koltai MZ, Wagner M, Kolonics I, Pogatsa G. (1982). Altered adrenergic responses of the coronary arterial bed in alloxan-diabetic dogs. *Experientia.* **38**(8): 934-935.

Pan ZK, Zuraw BL, Lung CC, Prossnitz ER, Browning DD, Ye RD. (1996). Bradykinin stimulates NF-kappaB activation and interleukin 1beta gene expression in cultured human fibroblasts. *J. Clin. Invest.* **98**(9): 2042-2049.

Park J, Freedman R, Bach C, Yee C, Rohrwild M, Kaminishi H, Müller-Esterl W, Jarnagin K. (1994). Bradykinin-B2 receptors in humans and rats: cDNA structures, gene structures, possible alternative splicing, and homology searching for subtypes. *Braz. J. Med. Biol. Res.* **27**(8): 1707-1724.

Parratt J. (1993). Endogenous myocardial protective (antiarrhythmic) substances. *Cardiovasc. Res.* **27**(5): 693-702.

Paula RD, Lima CV, Khosla MC, Santos RAS. (1995). Angiotensin-(1-7) potentiates the hypotensive effect of bradykinin in conscious rats. *Hypertension.* **26**(6 Pt 2): 1154-1159.

Pees C, Unger T, Gohlke P. (2003). Effect of angiotensin AT2 receptor stimulation on vascular cyclic GMP production in normotensive Wistar Kyoto rats. *Int. J. Biochem. Cell. Biol.* **35**(6): 963-972.

Pelouch V, Dixon IM, Golfman L, Beamish RE, Dhalla NS. (1993). Role of extracellular matrix proteins in heart function. *Mol. Cell. Biochem.* **129**(2): 101-120.

Pelzer T, de Jager T, Muck J, Stimpel M, Neyses L. (2002). Oestrogen action on the myocardium *in vivo*: specific and permissive for angiotensin-converting enzyme inhibition. *J. Hypertens.* **20**(5): 1001-1006.

Pelzer T, Schumann M, Neumann M, deJager T, Stimpel M, Serfling E, Neyses L. (2000). 17beta-estradiol prevents programmed cell death in cardiac myocytes. *Biochem. Biophys. Res. Commun.* **268**(1): 192-200.

Pheng LH, Nguyen-Le XK, Nsa Allogho S, Gobeil F, Regoli D. (1997). Kinin receptors in the diabetic mouse. *Can. J. Physiol. Pharmacol.* **75**(6): 609-611.

Penpargkul S, Schaible T, Yipintsoi T, Scheuer J. (1980). The effect of Diabetes on Performance and Metabolism of Rat Hearts. *Circ. Res.* **47**(6): 911-921.

Pesquero JB, Araujo RC, Heppenstall PA, Stucky CL, Silva JA Jr, Walther T, Oliveira SM, Pesquero JL, Paiva AC, Calixto JB, Lewin GR, Bader M. (2000). Hypoalgesia and altered inflammatory responses in mice lacking kinin B1 receptors. *Proc. Natl. Acad. Sci. U S A.* **97**(14): 8140-8145.

Pesquero JB, Bader M. (1998). Molecular biology of the kallikrein-kinin system: from structure to function. *Braz J Med. Biol. Res.* **31**(9): 1197-1203.

Pesquero JB, Lindsey CJ, Paiva AC, Ganten D, Bader M. (1996a). Transcriptional regulatory elements in the rat bradykinin B2 receptor gene. *Immunopharmacology.* **33**(1-3): 36-41.

Pesquero JB, Lindsey CJ, Zeh K, Paiva AC, Ganten D, Bader M. (1994). Molecular structure and expression of rat bradykinin B2 receptor gene. Evidence for alternative splicing. *J. Biol. Chem.* **269**(43): 26920-26905.

Pesquero JB, Oliveira SM, Pesquero J, Roscher AA, Metzger R, Ganten D, Bader M. (1996b). Molecular cloning of rodent Bradykinin B1 receptor genes. *Peptide Receptors Symposium, Montreal, Canada*: abstract II.0.5.

Pesquero JB, Pesquero JL, Oliveira SM, Roscher AA, Metzger R, Ganten D, Bader M. (1996c). Molecular cloning and functional characterization of a mouse bradykinin B1 receptor gene. *Biochem. Biophys. Res. Commun.* **220**(1): 219-225.

Pesquero JB, Pesquero JL, Oliveira SM, Roscher AA, Metzger R, Ganten D, Bader M. (1996). Molecular cloning and functional characterization of a mouse bradykinin B1 receptor gene. *Biochem. Biophys. Res. Commun.* **220**(1): 219-225.

Pessina AC, Sacchetto A, Rossi GP. (1997). Left ventricular anatomy and function in primary aldosteronism and renovascular hypertension. *Adv. Exp. Med. Biol.* **432**: 63-69.

Pfeffer MA. (1995). Left ventricular remodeling after acute myocardial infarction. *Annu. Rev. Med.* **46**: 455-466.

Pfeffer JM, Fischer TA, Pfeffer MA. (1995). Angiotensin-converting enzyme inhibition and ventricular remodeling after myocardial infarction. *Annu. Rev. Physiol.* **57**: 805-826.

Phagoo SB, Poole S, Leeb-Lundberg LM. (1999). Autoregulation of bradykinin receptors: agonists in the presence of interleukin-1 β shift the repertoire of receptor subtypes from B2 to B1 in human lung fibroblasts. *Mol. Pharmacol.* **56**(2): 325-333.

Phagoo SB, Yaqoob M, Herrera-Martinez E, McIntyre P, Jones C, Burgess GM. (2000). Regulation of bradykinin receptor gene expression in human lung fibroblasts. *Eur. J. Pharmacol.* **397**(2-3): 237-246.

Pinto YM, Bader M, Pesquero JB, Tschöpe C, Schöltens E, van Gilst WH, Buikema H. (2000). Increased kallikrein expression protects against cardiac ischemia. *FASEB J.* **14**(13): 1861-1863.

Pitt B, Mason J, Conti CR, Colman RW. (1969). Observations on the plasma kallikrein system during myocardial ischemia. *Trans. Assoc. Am. Physicians.* **82**: 98-108.

Pizard A, Blaukat A, Müller-Esterl W, Alhenc-Gelas F, Rajerison RM. (1999). Bradykinin-induced internalization of the human B2 receptor requires phosphorylation of three serine and two threonine residues at its carboxyl tail. *J. Biol. Chem.* **274**(18): 12738-12747.

Pizard A, Marchetti J, Allegrini J, Alhenc-Gelas F, Rajerison RM. (1998). Negative cooperativity in the human bradykinin B2 receptor. *J. Biol. Chem.* **273**(3): 1309-1315.

Powell SJ, Slynn G, Thomas C, Hopkins B, Briggs I, Graham A. (1993). Human bradykinin B2 receptor: nucleotide sequence analysis and assignment to chromosome 14. *Genomics.* **15**(2): 435-438.

Praddaude F, Tack I, Emond C, Bascands JL, Girolami JP, Tran-Van T, Regoli D, Ader JL. (1995). *In vivo* and *in vitro* homologous desensitization of rat glomerular bradykinin B2 receptors. *Eur. J. Pharmacol.* **294**(1): 173-182.

Prado GN, Mierke DF, LeBlanc T, Manseau M, Taylor L, Yu J, Zhang R, Pal-Ghosh R, Polgar P. (2001). Role of hydroxyl containing residues in the intracellular region of rat bradykinin B(2) receptor in signal transduction, receptor internalization, and resensitization. *J. Cell. Biochem.* **83**(3): 435-447.

Prado GN, Mierke DF, Pellegrini M, Taylor L, Polgar P. (1998). Motif mutation of bradykinin B2 receptor second intracellular loop and proximal C terminus is critical for signal transduction, internalization, and resensitization. *J. Biol. Chem.* **273**(50): 33548-33555.

Prado GN, Taylor L, Polgar P. (1997). Effects of intracellular tyrosine residue mutation and carboxyl terminus truncation on signal transduction and internalization of the rat bradykinin B2 receptor. *J. Biol. Chem.* **272**(23): 14638-14642.

Prado GN, Taylor L, Zhou X, Ricupero D, Mierke DF, Polgar P. (2002). Mechanisms regulating the expression, self-maintenance, and signaling-function of the bradykinin B2 and B1 receptors. *J. Cell. Physiol.* **193**(3): 275-286.

Prestridge DS. (1995). Predicting Pol II Promoter Sequences Using Transcription Factor Binding Sites. *J. Mol. Biol.* **249**: 923-932.

Raidoo DM, Ramsaroop R, Naidoo S, Müller-Esterl W, Bhoola KD. (1997). Kinin receptors in human vascular tissue: their role in atheromatous disease. *Immunopharmacology.* **36**(2-3): 153-160.

Rakieten N, Rakieten ML, Nadkarni MV. (1963). Studies on the diabetogenic action of streptozotocin (NSC-37917). *Cancer Chemother. Rep.* **29**: 91-98.

Ram PT, Iyengar RG. (2001). Protein coupled receptor signaling through the Src and Stat3 pathway: role in proliferation and transformation. *Oncogene.* **26**(13): 1601-1606.

Reese MG, Eeckman FH. (1995). Novel Neural Network Algorithms for Improved Eukaryotic Promoter Site Recognition. *Talk for The seventh international Genome sequencing and analysis conference.* Hyatt Regency, Hilton Head Island, South Carolina September 16-20,

Regoli D, Barabe J. (1980). Pharmacology of bradykinin and related kinins. *Pharmacol. Rev.* **32**(1): 1-46.

Regoli D, Barabe J, Marceau F, Couture R, Gaudreau P. (1980). Vasoactive polypeptide receptors. *Union Med. Can.* **109**(9): 1315-1322.

Regoli DC, Marceau F, Lavigne J. (1981). Induction of beta 1-receptors for kinins in the rabbit by a bacterial lipopolysaccharide. *Eur. J. Pharmacol.* **71**(1): 105-15.

Rehbock J, Miska K, Buchinger P. (1999). Induction of the bradykinin B2-receptor, but not of the bradykinin B1-receptor, by interleukin-1beta in cultivated human decidua-derived cells. *Immunopharmacology.* **43**(2-3): 235-239.

Rerup CC. (1970). Drugs producing diabetes through damage of the insulin secreting cells. *Pharmacol. Rev.* **22**(4): 485-518.

Rett K, Maerker E, Renn W, van Gilst W, Haering HU. (1997). Perfusion-independent effect of bradykinin and fosinoprilate on glucose transport in Langendorff rat hearts. *Am. J. Cardiol.* **80**(3A): 143A-147A.

Rett K, Wicklmayr M, Dietze GJ. (1990). Metabolic effects of kinins: historical and recent developments. *J. Cardiovasc. Pharmacol.* **15**(s6): S57-59.

Rett K, Wicklmayr M, Dietze GJ, Häring HU. (1996). Insulin-induced glucose transporter (GLUT1 and GLUT4) translocation in cardiac muscle tissue is mimicked by bradykinin. *Diabetes.* **45**(1): S66-69.

Rhaleb NE, Peng H, Alfie ME, Shesely EG, Carretero OA. (1999). Effect of ACE inhibitor on DOCA-salt- and aortic coarctation-induced hypertension in mice: do kinin B2 receptors play a role? *Hypertension.* **J33**(1 Pt 2): 329-334.

Rhaleb NE, Yang XP, Nanba M, Shesely EG, Carretero OA. (2001). Effect of Chronic Blockade of the Kallikrein-Kinin System on the Development of Hypertension in Rats. *Hypertension.* **37**(1): 121-128.

Ricupero DA, Romero JR, Rishikof DC, Goldstein RH. (2000). Des-Arg(10)-kallidin engagement of the B1 receptor stimulates type I collagen synthesis via stabilization of connective tissue growth factor mRNA. *J. Biol. Chem.* **275**(17): 12475-12480.

Riede U. (1999). Allgemeine und spezielle Pathologie (4. Auflage). *Thieme Verlag.*

Rios CD, Jordan BA, Gomes I, Devi LA. (2001). G-protein-coupled receptor dimerization: modulation of receptor function. *Pharmacol. Ther.* **92**(2-3): 71-87.

Riva E, Andreoni G, Bianchi R, Latini R, Luvara G, Jeremic G, Traquandi C, Tuccinardi L. (1998). Changes in diastolic function and collagen content in normotensive and hypertensive rats with long-term streptozotocin-induced diabetes. *Pharmacol. Res.* **37**(3): 233-240.

Rocha e Silva M, Beraldo WT, Rosenfeld G. (1949) Bradykinin hypotensive and smooth muscle stimulating factor released from plasma globulins by snake venoms and trypsin. *Am. J. Physiol.* **156**: 261-265.

Rosen P, Ballhausen T, Stockklauser K. (1996). Impairment of endothelium dependent relaxation in the diabetic rat heart: mechanisms and implications. *Diabetes. Res. Clin. Pract.* **31** Suppl: S143-155.

Rösen P, Eckel J, Reinauer H. (1983). Influence of bradykinin on glucose uptake and metabolism studied in isolated cardiac myocytes and isolated perfused rat hearts. *Hoppe Seylers Z. Physiol. Chem.* **364**(10): 1431-1438.

Rösen P, Pogatsa G, Tschöpe D, Addicks K, Reinauer H. (1992). Diabetic cardiopathy. Pathophysiologic concepts and therapeutic approaches. *Klin. Wochenschr.* **69**(29): 3-15.

Rösen P, Rösen R, Hohl C, Reinauer H, Klaus W. (1984). Reduced transcortical exchange and prostaglandin synthesis in diabetic rat heart. *Am. J. Physiol.* **247**(4Pt2): H563-569.

Rosenkranz S, Nickenig G, Flesch M, Cremers B, Schnabel P, Lenz O, Krause T, Ganten D, Hoffmann S, Böhm M. (1997). Cardiac angiotensin II receptors: studies on functional coupling in Sprague-Dawley rats and TGR(alphaMHC-hAT1) transgenic rats. *Eur. J. Pharmacol.* **330**(1): 35-46.

Rytter L, Troelsen S, Beck-Nielsen H. (1985). Prevalence and mortality of acute myocardial infarction in patients with diabetes. *Diabetes Care.* **8**(3): 230-234.

Sabourin T, Morissette G, Bouthillier J, Levesque L, Marceau F. (2002). Expression of kinin B(1) receptor in fresh or cultured rabbit aortic smooth muscle: role of NF-kappa B. *Am. J. Physiol. Heart Circ. Physiol.* **283**(1): H227-237.

Saed GM, Carretero OA, MacDonald RJ, Scicli AG. (1990). Kallikrein messenger RNA in rat arteries and veins. *Circ. Res.* 1990 **67**(2): 510-516.

Saifudeen Z, Du H, Dipp S, El-Dahr SS. (2000). The bradykinin type 2 receptor is a target for p53-mediated transcriptional activation. *J. Biol. Chem.* **275**(20): 15557-15562.

Saifudeen ZR, El-Dahr SS. (2001). Mus musculus bradykinin type 2 receptor (B2R) gene promoter region. Unpublished *NCBI Acc*: AF411045.

Sambrook J, Fritsch EF, Maniatis T. (1989). *Molecular cloning: A Laboratory Manual* (Cold Spring Harbour: Cold Spring Harbour Laboratory).

Santos RA, Simoes e Silva AC, Maric C, Silva DM, Machado RP, de Buhr I, Heringer-Walther S, Pinheiro SV, Lopes MT, Bader M, Mendes EP, Lemos VS, Campagnole-Santos MJ, Schultheiss HP, Speth R, Walther T. (2003). Angiotensin-(1-7) is an endogenous ligand for the G protein-coupled receptor Mas. *Proc. Natl. Acad. Sci. U S A.* **100**(14): 8258-8263.

Santos RAS, Campagnole-Santos MJ, Andrade SP. (2000). Angiotensin-(1-7): an update. *Regul. Pept.* **91**: 45-62.

Sawant S, Snyman C, Bhoola K. (2001). Comparison of tissue kallikrein and kinin receptor expression in gastric ulcers and neoplasms. *Int. Immunopharmacol.* **1**(12): 2063-2080.

Scicli AG, Carbini LA, Carretero OA. (1990). The molecular biology of the kallikrein-kinin system: II. The rat gene family. *J. Hypertens.* **11**(8): 775-780.

Schachter M. (1970). Bradykinin, Kallidin and Kallikrein. *Springer, Berlin*: 585-588.

Schachter M. (1980). Kallikreins (kininogenases): a group of serine proteases with bioregulatory actions. *Pharmacol. Rev.* **31**: 1-17.

Schanstra JP, Alric C, Marin-Castano ME, Girolami JP, Bascands JL. (1999). Renal bradykinin receptors: localisation, transduction pathways and molecular basis for a possible pathological role (review). *Int. J. Mol. Med.* **3**(2): 185-191.

Schanstra JP, Girolami JP, Bascands JL. (1999). Rat bradykinin B1 gene, promoter region, exon 1, intron 1, and exon 2. Unpublished *NCBI Acc*: AF114406.

Schanstra JP, Marin-Castano ME, Alric C, Pesquero JB, Claire M, Girolami JP, Bascands JL. (1999). Homologous and heterologous induction of the human bradykinin B1-receptor and B1-receptor localisation along the rat nephron. *Immunopharmacology.* **45**(1-3): 29-34.

Sharma JN, Uma K, Yusof AP. (1998). Left ventricular hypertrophy and its relation to the cardiac kinin-forming system in hypertensive and diabetic rats. *Int. J. Cardiol.* **63**(3): 229-35.

Schaub MC, Hefti MA, Harder BA, Eppenberger HM. (1977). Various hypertrophic stimuli induce distinct phenotypes in cardiomyocytes. *J. Mol. Med.* **75**(11-12): 901-920.

Schini VB, Boulanger C, Regoli D, Vanhoutte PM. (1999). Bradykinin stimulates the production of cyclic GMP via activation of B2 kinin receptors in cultured porcine aortic endothelial cells. *J. Pharmacol. Exp. Ther.* **252**(2): 581-585.

Schmaier AH, Kuo A, Lundberg D, Murray S, Cines DB. (1988). The expression of high molecular weight Kininogen on human umbilical vein endothelial cells. *J. Biol. Chem.* **263**: 16327-16333.

Schmaier AH, Smith PM, Purdon AD, White JG, Colman RW. (1986). High molecular weight Kininogen. Localisation in the unstimulated and activated platelet and activation by a platelet calpain (s). *Blood.* **67**: 119-130.

Schmaier AH. (2003). The Kallikrein-kinin and the renin-angiotensin systems have a multilayered interaction. *Am. J. Physiol. Regul. Integr. Comp. Physiol.* **285**: R1-13.

Schmidlin F, Scherrer D, Daeffler L, Bertrand C, Landry Y, Gies JP. (1998). Interleukin-1beta induces bradykinin B2 receptor gene expression through a prostanoid cyclic AMP-dependent pathway in human bronchial smooth muscle cells. *Mol. Pharmacol.* **53**(6): 1009-1015.

Schölkens BA. (1996). Kinins in the cardiovascular system. *Immunopharmacology.* **33**(1-3): 209-216.

Schöneberg T, Schultz G, Gudermann T. (1999). Structural basis of G protein-coupled receptor function. *Mol. Cell. Endocrinol.* **25**; 151(1, 2): 181-193.

- Schunkert H, Dzau VJ, Tang SS, Hirsch AT, Apstein CS, Lorell BH. (1990).** Increased rat cardiac angiotensin converting enzyme activity and mRNA expression in pressure overload left ventricular hypertrophy. Effects on coronary resistance, contractility, and relaxation. *J. Clin. Invest.* **86**(6): 1913-1920.
- Schunkert H, Hense HW, Holmer SR, Stender M, Perz S, Keil U, Lorell BH, Riegger GA. (1994).** Association between a deletion polymorphism of the angiotensin-converting-enzyme gene and left ventricular hypertrophy. *N. Engl. J. Med.* **330**(23): 1634-1638.
- Schunkert H, Jackson B, Tang SS, Schoen FJ, Smits JF, Apstein CS, Lorell BH. (1993).** Distribution and functional significance of cardiac angiotensin converting enzyme in hypertrophied rat hearts. *Circulation.* **87**(4): 1328-1339.
- Seabrook GR, Bowery BJ, Heavens R, Brown N, Ford H, Sirinathsinghi DJ, Borkowski JA, Hess JF, Strader CD, Hill RG. (1997).** Expression of B1 and B2 bradykinin receptor mRNA and their functional roles in sympathetic ganglia and sensory dorsal root ganglia neurones from wild-type and B2 receptor knockout mice. *Neuropharmacology.* **36**(7): 1009-1017.
- Sealey JE, Atlas SA, Laragh JH. (1978).** Linking the kallikrein and renin systems via activation of inactive renin: new data and a hypothesis. *Am. J. Med.* **65**(6): 994-1000.
- Selbie LA, Hill SJ. (1998).** G protein-coupled-receptor cross-talk: the fine-tuning of multiple receptor-signalling pathways. *Trends Pharmacol. Sci.* **19**(3): 87-93.
- Semenkovich CF, Heinecke JW. (1997).** The mystery of diabetes and atherosclerosis: time for a new plot. *Diabetes.* **46**(3): 327-334.
- Seta Y, Kanda T, Tanaka T, Arai M, Sekiguchi K, Yokoyama T, Kurimoto M, Tamura J, Kurabayashi M. (2000).** Interleukin 18 in acute myocardial infarction. *Heart* **84**(6): 668-669.
- Shams M, Sisi P, Ahmed A. (1996).** Localization of bradykinin type II receptor mRNA in human endometrium. *Mol. Hum. Reprod.* **2**(1): 35-39.
- Sharma JN, Kesavarao U. (1996).** Cardiac kallikrein in hypertensive and normotensive rats with and without diabetes. *Immunopharmacology.* **33**(1-3): 341-343.
- Sharma JN, Kesavarao U. (2002).** Effect of captopril on urinary kallikrein, blood pressure and myocardial hypertrophy in diabetic spontaneously hypertensive rats. *Pharmacology.* **64**(4): 196-200.
- Sharma JN, Uma K, Yusof AP. (1998).** Left ventricular hypertrophy and its relation to the cardiac kinin-forming system in hypertensive and diabetic rats. *Int. J. Cardiol.* **63**(3): 229-235.

Shiuchi T, Cui TX, Wu L, Nakagami H, Takeda-Matsubara Y, Iwai M, Horiuchi M. (2002). ACE inhibitor improves insulin resistance in diabetic mouse via bradykinin and NO. *Hypertension*. **40**(3): 329-334.

Sigusch HH, Campbell SE, Weber KT. (1996). Angiotensin II-induced myocardial fibrosis in rats: role of nitric oxide, prostaglandins and bradykinin. *Cardiovasc. Res.* **31**(4): 546-554.

Silva JA Jr, Araujo RC, Baltatu O, Oliveira SM, Tschöpe C, Fink E, Hoffmann S, Plehm R, Chai KX, Chao L, Chao J, Ganten D, Pesquero JB, Bader M. (2000). Reduced cardiac hypertrophy and altered blood pressure control in transgenic rats with the human tissue kallikrein gene. *FASEB J.* **14**(13): 1858-1860.

Silva RM. (1951). Bradykinin; mechanism of its release by Trypsin and kallikrein. *Arch. Int. Pharmacodyn. Ther.* **88**(3): 271-282.

Silvestre JS, Bergaya S, Tamarat R, Duriez M, Boulanger CM, Levy BI. (2001). Proangiogenic effect of angiotensin-converting enzyme inhibition is mediated by the bradykinin B(2) receptor pathway. *Circ. Res.* **89**(8): 678-683.

Siragy HM, de Gasparo M, El-Kersh M, Carey RM. (2001). Angiotensin-converting enzyme inhibition potentiates angiotensin II type 1 receptor effects on renal bradykinin and cGMP. *Hypertension*. **38**(2): 183-186.

Siragy HM, Carey RM. (1999). Protective role of the angiotensin AT2 receptor in a renal wrap hypertension model. *Hypertension*. **33**(5): 1237-1242.

Siragy HM, Jaffa AA, Margolius HS, Carey RM. (1996). Renin-angiotensin system modulates renal bradykinin production. *Am. J. Physiol.* **271**(4 Pt 2): R1090-1095.

Skidgel RA, Erdös EG. (1989). Angiotensin I converting enzyme. *Adv. Exp. Med. Biol.* **247A**: 25–28.

Skidgel RA, Erdös EG. (1998a). Cellular carboxypeptidases. *Immunol. Rev.* **161**: 129-41.

Skidgel RA, Erdös EG. (1998b). Enzymatic breakdown of bradykinin. In: Said SI, ed. *Pro-inflammatory and Anti-inflammatory Peptides*. New York: NY: Marcel Dekker: 459–476.

Smith JW, Marcus FI, Serokman R. (1984). Prognosis of patients with diabetes mellitus after acute myocardial infarction. *Am. J. Cardiol.* **54**(7): 718-721.

Smith JA, Webb C, Holford J, Burgess GM. (1995). Signal transduction pathways for B1 and B2 bradykinin receptors in bovine pulmonary artery endothelial cells. *Mol. Pharmacol.* **47**(3): 525-534.

Song Q, Wang DZ, Harley RA, Chao L, Chao J. (1996). Cellular localization of low-molecular-weight kininogen and bradykinin B2 receptor mRNAs in human kidney. *Am J. Physiol.* **270**(6 Pt 2):F919-26.

Soskic V, Nyakatura E, Roos M, Müller-Esterl W, Godovac-Zimmermann J. (1999). Correlations in palmitoylation and multiple phosphorylation of rat Bradykinin B2 receptor in Chinese hamster ovary cells. *J. Biol. Chem.* **274**(13): 8539-8545.

Southern EM. (1975). Detection of specific sequences among DNA fragments separated by gel electrophoresis. *J. Mol. Biol.* **98**: 503-517.

Souza Dos Santos RA, Passaglio KT, Pesquero JB, Bader M, Simoes E Silva AC. (2001). Interactions between angiotensin-(1-7), kinins, and angiotensin II in kidney and blood vessels. *Hypertension.* **38**(3 Pt 2): 660-664.

Spillman F, Altmann C, Scheeler M, Barbosa M, Westermann D, Schultheiss HP, Walther T, Tschöpe C. (2002). Regulation of cardiac Bradykinin B1- and B2-receptor mRNA in experimental ischemic, diabetic and pressure-overload-induced cardiomyopathie. *Int Immunopharmacol.* **2**: 1823-1832.

Spitznagel H, Stauss HM, Gohlke P, Zhu YZ, Zhu YC, Falkenhahn M, Unger T. (1996). Angiotensin II and bradykinin in hypertensive heart disease and myocardial infarction. *High Blood Press.* **5**: 119-123.

Stauss HM, Zhu YC, Redlich T, Adamiak D, Mott A, Kregel KC, Unger T. (1994). Angiotensin-converting enzyme inhibition in infarct-induced heart failure in rats: bradykinin versus angiotensin II. *J. Cardiovasc. Risk.* **1**(3): 255-262.

Stoll M, Meffert S, Stroth U, Unger T. (1995). Growth or antigrowth: angiotensin and the endothelium. *J. Hypertens.* **13**(12 Pt 2): 1529-1534.

Stoll M, Steckelings UM, Paul M, Bottari SP, Metzger R, Unger T. (1995). The angiotensin AT2-receptor mediates inhibition of cell proliferation in coronary endothelial cells. *J. Clin Invest.* **95**(2): 651-657.

Stout PA, Villegas J, Kim H. (2001). Enhancing learning through use of interactive tools on health-related websites. *Health Educ. Res.* **16**(6): 721-733.

Strader CD, Tung MF, Graziano MP, Tota MR. (1995). The family of G-protein-coupled receptors. *FASEB J.* **9**: 745-754.

Strawn WB, Gallagher PE, Tallant EA, Ganten D, Ferrario CM. (1999). Angiotensin II AT1-receptor blockade inhibits monocyte activation and adherence in transgenic (mRen2)²⁷ rats. *J. Cardiovasc. Pharmacol.* **33**(3): 341-351.

Streyer L. (1991). Biochemie. *Spectrum Akad. Verlag, Berlin*: 1011-1040.

Su JB, Houel R, Heloïre F, Barbe F, Beverelli F, Sambin L, Castaigne A, Berdeaux A, Crozatier B, Hittinger L. (2000). Stimulation of bradykinin B(1) receptors induces vasodilation in conductance and resistance coronary vessels in conscious dogs: comparison with B(2) receptor stimulation. *Circulation*. **101**(15): 1848-1853.

Sun Y, Diaz-Arias AA, Weber KT. (1994). Angiotensin-converting enzyme, bradykinin, and angiotensin II receptor binding in rat skin, tendon, and heart valves: an *in vitro*, quantitative autoradiographic study. *J. Lab. Clin. Med.* **123**(3): 372-377.

Sun Y, Weber KT. (2000). Infarct scar: a dynamic tissue. *Cardiovasc. Res.* **46**(2): 250-256.

Taketo M, Yokoyama S, Rochelle J, Kimura Y, Higashida H, Taketo M, Seldin MF. (1995). Mouse B2 bradykinin receptor gene maps to distal chromosome 12. *Genomics*. **27**(1): 222-223.

Tang W, Devereux RB, Rao DC, Oberman A, Hopkins PN, Kitzman DW, Arnett DK. (2002). Associations between angiotensinogen gene variants and left ventricular mass and function in the HyperGEN study. *Am. Heart J.* **143**(5): 854-860.

Tashiro H, Shimokawa H, Yamamoto K, Nagano M, Momohara M, Muramatu K, Takeshita A. (1995). Monocyte-related cytokines in acute myocardial infarction. *Am. Heart. J.* **130**(3 Pt 1): 446-452.

The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. (1993). Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. *Lancet*. **342**(8875): 821-828.

Thomas WG, Brandenburger Y, Autelitano DJ, Pham T, Qian H, Hannan RD. (2002). Adenoviral-directed expression of the type 1A angiotensin receptor promotes cardiomyocyte hypertrophy via transactivation of the epidermal growth factor receptor. *Circ. Res.* **90**(2): 135-142.

Tiffany CW, Burch RM. (1989). Bradykinin stimulates tumor necrosis factor and interleukin-1 release from macrophages. *FEBS Lett.* **247**(2): 189-192.

Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. (2000). A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. *J. Biol. Chem.* **275**(43): 33238-33243.

Toda N, Bian K, Akiba T, Okamura T. (1987). Heterogeneity in mechanisms of bradykinin action in canine isolated blood vessels. *Eur. J. Pharmacol.* **135**(3): 321-329.

Tooke JE. (1987). The microcirculation in diabetes. *Diabet. Med.* **4**(3): 189-196.

Topol Eric J. (2002). Textbook of Cardiovascular Medicine (2nd edition). *Lippincott Williams & Wilkins*, ISBN: 0-7817-3225-5

Touyz RM, Endemann D, He G, Li JS, Schiffrin EL. (1999). Role of AT2 receptors in angiotensin II-stimulated contraction of small mesenteric arteries in young SHR. *Hypertension*. **33**(1 Pt 2): 366-372.

Trevisani M, Schmidlin F, Tognetto M, Nijkamp FP, Gies JP, Frossard N, Amadesi S, Folkerts G, Geppetti P. (1999). Evidence for *in vitro* expression of B1 receptor in the mouse trachea and urinary bladder. *Br. J. Pharmacol.* **126**(6): 1293-1300.

Tropea MM, Gummelt D, Herzig MS, Leeb-Lundberg LM. (1993). B1 and B2 kinin receptors on cultured rabbit superior mesenteric artery smooth muscle cells: receptor-specific stimulation of inositol phosphate formation and arachidonic acid release by des-Arg9-bradykinin and bradykinin. *J. Pharmacol. Exp. Ther.* **264**(2): 930-937.

Tschöpe C, Gavrilluk V, Reinecke A, Seidl U, Riester U, Hilgenfeld U, Ritz E, Unger T. (1996). Bradykinin excretion is increased in several hyperglycemic streptozotocin-diabetic rats. *Immunopharmacology*. **33**(1-3): 344-348.

Tschöpe C, Gohlke P, Zhu YZ, Linz W, Schölkens B, Unger T. (1997b). Antihypertensive and cardioprotective effects after angiotensin-converting enzyme inhibition: role of kinins. *J. Card. Fail.* **3**(2): 133-148.

Tschöpe C, Heringer-Walther S, Koch M, Spillmann F, Wendorf M, Bader M, Schultheiss H-P, Walther T. (2000b). Myocardial bradykinin B2-receptor expression at different time points after induction of myocardial infarction. *J. Hypertens.* **18**: 223-228.

Tschöpe C, Heringer-Walther S, Koch M, Spillmann F, Wendorf M, Leitner E, Schultheiss HP, Walther T. (2000c). Up-regulation of bradykinin B1-receptor expression after myocardial infarction. *Br. J. Pharmacol.* **129**(8): 1537- 1538.

Tschöpe C, Heringer-Walther S, Walther T. (2000a). Regulation of the kinin receptors after induction of myocardial infarction: a mini review. *Braz. J. Med. Biol. Res.* **33**(6): 701-708.

Tschöpe C, Koch M, Spillmann F, Heringer-Walther S, Mochmann HC, Stauss H, Bader M, Unger Th, Schultheiss HP, Walther T. (1999c). Upregulation of the cardiac bradykinin B2 receptor after myocardial infarction. *Immunopharmacology*. **44**(1-2): 111-117.

Tschöpe C, Reinecke A, Seidl U, Yu M, Gavrilluk V, Riester U, Gohlke P, Graf K, Bader M, Hilgenfeldt U, Pesquero JB, Ritz E, Unger T. (1999a). Functional, biochemical, and molecular investigations of renal kallikrein-kinin system in diabetic rats. *Am. J. Physiol.* **277**(6 Pt 2): H2333-2340.

Tschöpe D, Rösen P. (1998). Heart disease in diabetes mellitus: a challenge for early diagnosis and intervention. *Exp. Clin. Endocrinol. Diabetes.* **106**(1): 16-24.

Tschöpe C, Schultheiss HP. (2000). Behandlung der Herzinsuffizienz. *Der Kassenarzt.* **40**(6): 33-38.

Tschöpe C, Schultheiss HP, Walther T. (2002). Multiple interactions between the renin-angiotensin and the kallikrein-kinin systems: role of ACE inhibition and AT₁ receptor blockade. *J. Cardiovasc. Pharmacol.* **39**(4): 478-487.

Tschöpe C, Spillmann F, Altmann C, Koch M, Westermann D, Dhayat N, Dhayat S, Bascands JL, Gera L, Hoffmann S, Schultheiss HP, Walther T. (2004). The bradykinin B1 receptor contributes to the cardioprotective effects of AT₁ blockade after experimental myocardial infarction. *Cardiovasc. Res.* **61**(3): 559-569.

Tschöpe C, Walther T, Escher F, Spillmann F, Du J, Altmann C, Schimke I, Bader M, Sanchez-Ferrer CF, Schultheiss HP, Noutsias M. (2005). Transgenic activation of the Kallikrein-kinin system inhibits intramyocardial inflammation, endothelial dysfunction and oxidative stress in experimental diabetic cardiomyopathy. *FASEB J.* **19**(14): 2057-2059.

Tschöpe C, Walther T, Königer J, Spillmann F, Westermann D, Escher F, Pauschinger M, Pesquero JB, Bader M, Schultheiss HP, Noutsias M. (2004). Prevention of cardiac fibrosis and left ventricular dysfunction in diabetic cardiomyopathy in rats by transgenic expression of the human tissue Kallikrein gene. *FASEB J.* **18**(7): 828-835.

Tschöpe C, Walther T, Yu M, Reinecke A, Koch M, Seligmann C, Heringer SB, Pesquero JB, Bader M, Schultheiss H, Unger T. (1999b). Myocardial expression of rat bradykinin receptors and two tissue kallikrein genes in experimental diabetes. *Immunopharmacology.* **44**(1-2): 35-42.

Tschöpe C, Yu M, Reinecke A, Csikos T, Hilgenfeldt U, Pesquero JB, Ritz E, Unger T. (1997a). Renal expression of two rat kallikrein genes under diabetic conditions. *J. Hypertens.* **15**(12 Pt 2): 1711-1714.

Tsuchida S, Miyazaki Y, Matsusaka T, Hunley TE, Inagami T, Fogo A, Ichikawa I. (1999). Potent antihypertrophic effect of the bradykinin B2 receptor system on the renal vasculature. *Kidney Int.* **56**(2): 509-516.

Tsutsumi Y, Matsubara H, Masaki H, Kurihara H, Murasawa S, Takai S, Miyazaki M, Nozawa Y, Ozono R, Nakagawa K, Miwa T, Kawada N, Mori Y, Shibasaki Y, Tanaka Y, Fujiyama S, Koyama Y, Fujiyama A, Takahashi H, Iwasaka T. (1999). Angiotensin II type 2 receptor overexpression activates the vascular kinin system and causes vasodilation. *J. Clin. Invest.* **104**(7): 925-935.

Uehara S, Isogawa S, Sakamoto W, Hirayama A. (1988). Kallikrein-kinin system in diabetic patients. *Arzneimittelforschung*. **38**(5): 721-723.

Unger T. (2002). The role of the renin-angiotensin system in the development of cardiovascular disease. *Am. J. Cardiol.* **89**(2A): 3A-10A.

Vadlamudi RV, Rodgers RL, McNeill JH. (1982). The effect of chronic alloxan- and streptozotocin-induced diabetes on isolated rat heart performance. *Can. J. Physiol. Pharmacol.* **60**(7): 902-911.

Vaidehi N, Floriano WB, Trabanino R, Hall SE, Freddolino P, Choi EJ, Zamanakos G, Goddard WA 3rd. (2002). Prediction of structure and function of G protein-coupled receptors. *Proc. Natl. Acad. Sci. U S A.* **99**(20): 12622-12627.

van Berlo JH, Pinto YM. (2003). Polymorphisms in the RAS and cardiac function. *Int. J. Biochem. Cell. Biol.* **35**(6): 932-943.

Vanhoutte PM. (1989). Endothelium and control of vascular function. State of the Art lecture. *Hypertension*. **13**(6 Pt 2): 658-667.

Vanhoutte PM. (2004). Endothelial AT(2)-receptors: chicken or egg?. *Br. J. Pharmacol.* **136**(4): 481-483.

Van Iwaarden F, De Groot PG, Bouma BN. (1988). The binding of a high molecular weight Kininogen to cultured human endothelial cells. *J. Biol. Chem.* **263**: 4698-4703.

Vasan RS, Benjamin EJ, Larson MG, Leip EP, Wang TJ, Wilson PW, Levy D. (2002). Plasma natriuretic peptides for community screening for left ventricular hypertrophy and systolic dysfunction: the Framingham heart study. *JAMA.* **288**(10): 1252-1259.

Vianna RM, Calixto JB. (1998). Characterization of the receptor and the mechanisms underlying inflammatory response induces by desArg9-BK in mouse pleuritis. *Br. J. Pharmacol.* **123**(2): 281-291.

Vickers C, Hales P, Kaushik V, Dick L, Gavin J, Tang J, Godbout K, Parsons T, Baronas E, Hsieh F, Acton S, Patane M, Nichols A, Tummino P. (2002). Hydrolysis of biological peptides by human angiotensin-converting enzyme-related carboxypeptidase. *J. Biol. Chem.* **277**(17): 14838-14843.

Voino-Yasenetskaya TA, Bochkov VN, Tkachuk VA, Ryan US. (1990). Regulation by bradykinin of phosphoinositide metabolism in the endothelial cells of the pulmonary artery. *Biomed. Sci.* **1**(2): 160-164.

Waibel AH, Hanazawa T, Hinton GE, Shikano K, Lang KJ. (1989). Phoneme Recognition Using Time-Delay Neural Networks. *IEEE Transactions on Acoustic, Speech, and Signal Processing.* **(37)**3: 328-339

- Walden PD, Lefkowitz GK, Ittmann M, Lepor H, Monaco ME. (1999).** Mitogenic activation of human prostate-derived fibromuscular stromal cells by bradykinin. *Br J Pharmacol.* **127**(1): 220-226.
- Walsh DA and Fan T-P. (1997).** Bradykinin as a growth factor. In: The kinin system. *Academic Press, London.* 301-314.
- Walther T, Siems WE, Hauke D, Spillmann F, Dendorfer A, Krause W, Schultheiss HP, Tschöpe C. (2002).** AT1 receptor blockade increases cardiac bradykinin via neutral Endopeptidase after induction of myocardial infarction in rats. *FASEB J.* **16**(10): 1237-1241.
- Wang B, Dang A, Liu G. (2001).** Genetic variation in the promoter region of the beta2 bradykinin receptor gene is associated with essential hypertension in a Chinese Han population. *Hypertens. Res.* **24**(3): 299-302.
- Wang DZ, Ma JX, Chao L, Chao J. (1994).** Molecular cloning and sequence analysis of rat bradykinin B2 receptor gene. *Biochim. Biophys. Acta.* **1219**(1): 171-174.
- Wang DZ, Song Q, Chen LM, Chao L, Chao J. (1996).** Expression and cellular localization of tissue kallikrein-kinin system in human adrenal gland. *Am. J. Physiol.* **271**(3 Pt 2): F709-716.
- Wang G, Guo X, Floros J. (2005).** Differences in the translation efficiency and mRNA stability mediated by 5'-UTR splice variants of human SP-A1 and SP-A2 genes. *Am. J. Physiol. Lung Cell. Mol. Physiol.* **289**(3): L497-508.
- Wang Q, Hummler E, Nussberger J, Clement S, Gabbiani G, Brunner HR, Burnier M. (2002).** Blood pressure, cardiac, and renal responses to salt and deoxycorticosterone acetate in mice: role of Renin genes. *J. Am. Soc. Nephrol.* **13**(6): 1509-1516.
- Wang Q, Patton WF, Hechtman HB, Shepro D. (1997).** Activation of endothelial cell kinin receptors leads to intracellular calcium increases and filamin translocation: regulation by protein kinase C. *Cell. Signal.* **9**(8): 595-602.
- Wang ZQ, Moore AF, Ozono R, Siragy HM, Carey RM. (1998).** Immunolocalization of subtype 2 angiotensin II (AT2) receptor protein in rat heart. *Hypertension.* **32**: 78-83.
- Waterston RH, Lindblad-Toh K, Birney E et al. Mouse Genome Sequencing Consortium. (2002).** Initial sequencing and comparative analysis of the mouse genome. *Nature.* **420**(6915): 520-562.
- Webb M, McIntyre P, Phillips E. (1994).** B1 and B2 bradykinin receptors encoded by distinct mRNAs. *J. Neurochem.* **62**(4): 1247-1253.

Weber KT, Sun Y. (2000). Recruitable ACE and tissue repair in the infarcted heart. *J. Renin Angiotensin Aldosterone Syst.* **1**(4): 295-303.

Weber KT, Sun Y, Katwa LC, Cleutjens JP. (1995). Connective tissue: a metabolic entity?. *J. Mol. Cell. Cardiol.* **27**(1): 107-120. Erratum in: *J. Mol. Cell. Cardiol.* **27**(1): 107-120.

Werle E, Berek U. (1948). Zur Kenntnis des Kallikreins. *Angew. Chem.* **60A**: 53-57.

Werle E, Götze W, Keppler A. (1937). Über die Wirkung des Kallikreins auf den isolierten Darm und über eine neue darmkontrahierende Substanz. *Biochem. J.* **289**: 217-233.

Werle E, Grunz M. (1939). Zur Kenntnis der darmkontrahierenden, uteruserregenden und blutdrucksenkenden Substanz. *Biochem. Z.* **301**: 429-436.

Whitehead IP, Zohn IE, Der CJ. (2001). Rho GTPase-dependent transformation by G protein-coupled receptors. *Oncogene.* **20**(13): 1547-1555.

Wicklmayr M, Rett K, Baldermann H, Dietze G. (1989). The kallikrein/kinin system in the pathogenesis of hypertension in diabetes mellitus. *Diabete. Metab.* **15**(5Pt2): 306-310.

Wicklmayr M, Rett K, Fink E, Tschollar W, Baldermann H, Tymiec M, Dietze G, Mehnert H. (1989). Bradykinin is not liberated by working skeletal muscle in diabetes type II. *Horm. Metab. Res.* **21**(4): 222-223.

Widdop RE, Sampey DB, Jarrot B. (1999). Cardiovascular effects of angiotensin-(1-7) in conscious spontaneously hypertensive rats. *Hypertension.* **34**(Pt 2): 964-968.

Wiemer G, Schölkens BA, Becker RH, Busse R. (1991). Ramiprilat enhances endothelial autacoid formation by inhibiting breakdown of endothelium-derived bradykinin. *Hypertension.* **18**(4): 558-563.

Wilkinson M. (1988). RNA isolation: A mini-prep method. *Nucleic Acids Res.* **16**: 109-133.

Witherow FN, Helmy A, Webb DJ, Fox KA, Newby DE. (2001). Bradykinin contributes to the vasodilator effects of chronic angiotensin-converting enzyme inhibition in patients with heart failure. *Circulation.* **104**(18): 2177-2181.

Wollert KC, Drexler H. (1997). The kallikrein-kinin system in post-myocardial infarction cardiac remodeling. *Am. J. Cardiol.* **80**(3A): 158A-161A.

Wollert KC, Studer R, Doerfer K, Schieffer E, Holubarsch C, Just H, Drexler H. (1997). Differential effects of kinins on cardiomyocyte hypertrophy and interstitial collagen matrix in the surviving myocardium after myocardial infarction in the rat. *Circulation*. **95**(7): 1910-1917.

Wong PY, Williams GH, Colman RW. (1983). Studies on the renin-angiotensin system in a kininogen-deficient individual. *Clin. Sci. (Lond)*. **65**(2): 121-126.

Xie P, Browning DD, Hay N, Mackman N, Ye RD. (2000). Activation of NF-kappa B by bradykinin through a G alpha(q)- and G beta gamma-dependent pathway that involves phosphoinositide 3-kinase and Akt. *J. Biol. Chem*. **275**(32): 24907-24914.

Xiong W, Chen LM, Woodley-Miller C, Simson JA, Chao J. (1990). Identification, purification, and localization of tissue kallikrein in rat heart. *Biochem. J*. **267**(3): 639-646.

Xu J, Carretero OA, Sun Y, Shesely EG, Rhaleb NE, Liu YH, Liao TD, Yang JJ, Bader M, Yang XP. (2005). Role of the B1 kinin receptor in the regulation of cardiac function and remodeling after myocardial infarction. *Hypertension*. **45**(part 2): 747-753.

Yamazaki T, Komuro I, Yazaki Y. (1999). Role of the renin-angiotensin system in cardiac hypertrophy. *Am. J. Cardiol*. **83**(12A): 53H-57H.

Yanaga F, Hirata M, Koga T. (1991). Evidence for coupling of bradykinin receptors to a guanine-nucleotide binding protein to stimulate arachidonate liberation in the osteoblast-like cell line, MC3T3-E1. *Biochim. Biophys. Acta*. **1094**(2): 139-146.

Yang HY, Erdös EG, Levin Y. (1971). Characterization of a dipeptide hydrolase (kininase II: angiotensin I converting enzyme). *J. Pharmacol. Exp. Ther*. **177**(1): 291-300.

Yang HY, Erdös EG, Levin Y. (1970). A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. *Biochim. Biophys. Acta*. **214**(2): 374-376.

Yang HY, Erdös EG. (1967). Second kininase in human blood plasma. *Nature*. **215**(108): 1402-1403.

Yang Y, Mummy M, Romeo D, Wakefield LM. (1998). Identification of the start sites for the 1.9- and 1.4-kb rat transforming growth factor- β 1 transcripts and their effect on translational efficiency. *Gene*. **219**(3): 81-89.

Yang X, Polgar P. (1996). Genomic structure of the human bradykinin B1 receptor gene and preliminary characterization of its regulatory regions. *Biochem. Biophys. Res. Commun*. **222**(3): 718-725.

Yang X, Taylor L, Polgar P. (2001). p53 down-regulates human bradykinin B1 receptor gene expression. *J. Cell. Biochem.* **82**(1): 38-45.

Yang XP, Liu YH, Mehta D, Cavaasin MA, Shesely E, Xu J, Liu F, Carretero OA. (2001). Diminished cardioprotective response to inhibition of angiotensin-converting enzyme and angiotensin II type 1 receptor in B(2) kinin receptor gene knockout mice. *Circ. Res.* **88**(10): 1072-1079.

Yayama K, Hiyoshi H, Okamoto H. (2001). Expressions of bradykinin B2-receptor, kallikrein and kininogen mRNAs in the heart are altered in pressure-overload cardiac hypertrophy in mice. *Biol. Pharm. Bull.* **24**(1): 34-38.

Yayama K, Matsuoka S, Nagaoka M, Okamoto H, Shimazu E, Takano M, Okamoto H. (2003). Down-regulation of bradykinin B2-Receptor mRNA in rat heart in pressure-overload cardiac hypertrophy in the rat. *Biochem. Pharmacol.* **65**(6): 1017-1025.

Yayama K, Nagaoka M, Takano M, Okamoto H. (2000). Expression of kininogen, kallikrein and kinin receptor genes by rat cardiomyocytes. *Biochim. Biophys. Acta.* **1495**(1): 69-77.

Yosipiv IV, Dipp S, El-Dahr SS. (2001). Targeted disruption of the bradykinin B(2) receptor gene in mice alters the ontogeny of the renin-angiotensin system. *Am. J. Physiol. Renal Physiol.* **281**(5): F795-801.

Yoshida H, Zhang JJ, Chao L, Chao J. (2000). Kallikrein gene delivery attenuates myocardial infarction and apoptosis after myocardial ischemia and reperfusion. *Hypertension.* **35**(1 Pt 1): 25-31.

Young M, Funder JW. (2000). Aldosterone and the heart. *Trends. Endocrinol. Metab.* **11**(6): 224-226.

Yu J, Prado GN, Taylor L, Piserchio A, Gupta A, Mierke DF, Polgar P. (2002). Global chimeric exchanges within the intracellular face of the bradykinin B2 receptor with corresponding angiotensin II type Ia receptor regions: generation of fully functional hybrids showing characteristic signaling of the AT₁A receptor. *J. Cell. Biochem.* **85**(4): 809-819.

Yue P, Massie BM, Simpson PC, Long CS. (1998). Cytokine expression increases in nonmyocytes from rats with postinfarction heart failure. *Am. J. Physiol.* **275**(1 Pt 2): H250-258.

Zarich SW, Nesto RW. (1989). Diabetic cardiomyopathy. *Am. Heart J.* **118**(5Pt1): 1000-1012.

Zeng FY, Wess J. (1999). Identification and molecular characterization of m3 muscarinic receptor dimers. *J. Biol. Chem.* **274**(27): 19487-19497.

Zhang D, Gaussin V, Taffet GE, Belaguli NS, Yamada M, Schwartz RJ, Michael LH, Overbeek PA, Schneider MD. (2000). TAK1 is activated in the myocardium after pressure overload and is sufficient to provoke heart failure in transgenic mice. *Nat. Med.* **6**(5): 556-563.

Zhou G, Tyagi SC, Weber KT. (1993) Bradykinin regulates collagen turnover in cardiac fibroblasts. *Clin. Res.* **41**: 630A.

Zhou X, Polgar P, Taylor L. (1998). Roles for interleukin-1beta, phorbol ester and a post-transcriptional regulator in the control of bradykinin B1 receptor gene expression. *Biochem. J.* **330**(Pt 1): 361-366.

Zhou X, Prado GN, Taylor L, Yang X, Polgar P. (2000). Regulation of inducible bradykinin B1 receptor gene expression through absence of internalization and resensitization. *J. Cell. Biochem.* **78**(3): 351-362.

Zhu YC, Stauss HM, Bao G, Gohlke P, Zhu YZ, Redlich T, Unger T. (1995). Role of bradykinin in the antihypertensive and cardioprotective actions of converting enzyme inhibitors. *Can. J. Physiol. Pharmacol.* **73**(7): 827-831.

Zhu YC, Zhu YZ, Gohlke P, Stauss HM, Unger T. (1997). Effects of angiotensin-converting enzyme inhibition and angiotensin II AT₁ receptor antagonism on cardiac parameters in left ventricular hypertrophy. *Am J Cardiol.* **80**(3A): 110A-117A.

Zhu YZ, Zhu YC, Chung C, Spitznagel H, Sandmann S, Tschöpe C, Unger T. (1996). Increased gene expression of angiotensin AT₁ and AT₂ receptors in the acute phase of myocardial infarction. *Abstract book: Council for High Blood Pressure Research.*

Zhu YZ, Zhu YC, Li J, Schäfer H, Schmidt W, Yao T, Unger T. (2000). Effects of losartan on haemodynamic parameters and angiotensin receptor mRNA levels in rat heart after myocardial infarction. *J. Renin Angiotensin Aldosterone Syst.* **1**(3): 257-262.

Zychma MJ, Gumprecht J, Zukowska-Szczechowska E, Grzeszczak W. (1999). Polymorphisms in the genes encoding for human kinin receptors and the risk of end-stage renal failure: results of transmission/disequilibrium test. The End-Stage Renal Disease Study Group. *J. Am. Soc. Nephrol.* **10**(10): 2120-2124.